NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:14:58 ON 22 DEC 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:15:14 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0
DICTIONARY FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10761889B1.str



chain nodes :
9 10 11 12
ring nodes :

```
1  2  3  4  5  6  7  8
chain bonds :
1-9  4-11  5-10
ring bonds :
1-2  1-5  2-3  2-6  3-4  3-7  4-5  6-8  7-8
exact/norm bonds :
1-2  1-5  1-9  2-3  2-6  3-4  3-7  4-5  4-11  6-8  7-8
exact bonds :
5-10

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS


L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> l1 sam sss
SAMPLE SEARCH INITIATED 18:16:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       20 TO ITERATE

100.0% PROCESSED       20 ITERATIONS                                 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          132 TO      668
PROJECTED ANSWERS:               8 TO      329

L2            8 SEA SSS SAM L1

=> l1 sss full
FULL SEARCH INITIATED 18:16:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      405 TO ITERATE

100.0% PROCESSED      405 ITERATIONS                               124 ANSWERS
SEARCH TIME: 00.00.01

L3          124 SEA SSS FUL L1
```

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	167.59

FILE 'CAPLUS' ENTERED AT 18:16:31 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l3
L4 14 L3

=> d fbib abs hitstr 4 1-14

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:133079 CAPLUS
DN 138:188071
TI Peptidomimetics of biologically active metallopeptides
IN Sharma, Shubh D.; Shi, Yiqun; Rajpurohit, Ramesh; Wu, Zhijun
PA Palatin Technologies, Inc., USA
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2003013571	A1	20030220	WO 2002-US25574		20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-311404P	P	20010810
	CA 2462200	A1	20030220	CA 2002-2462200		20020812
				US 2001-311404P	P	20010810
				WO 2002-US25574	W	20020812

EP 1425029		A1	20040609	EP 2002-768507		20020812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
				US 2001-311404P	P	20010810
				WO 2002-US25574	W	20020812
JP 2005504043		T	20050210	JP 2003-518577		20020812
				US 2001-311404P	P	20010810
				WO 2002-US25574	W	20020812
US 2004152134		A1	20040805	US 2004-761889		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
US 2004157264		A1	20040812	US 2004-762079		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-474497P	P	20030530
US 2004167201		A1	20040826	US 2004-776657		20040210
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
US 2004171520		A1	20040902	US 2004-776419		20040210
				US 2001-311404P	P	20010810
				WO 2002-US25574	A1	20020812
US 2005130988		A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
US 2005124636		A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
US 2005176728		A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430

PATENT FAMILY INFORMATION:

FAN 2004:633168

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004152134	A1	20040805	US 2004-761889		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,					

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

			US 2001-311404P	P	20010810
US 2005130988	A1	20050616	US 2005-36282		20050114
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-536606P	P	20040114
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
US 2005124636	A1	20050609	US 2005-40838		20050121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430

FAN 2004:652533

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 2004157264	A1	20040812	US 2004-762079		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

			US 2001-311404P	P	20010810
WO 2005102340	A1	20051103	WO 2004-US1462		20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2003-474497P	P	20030530
US 2005130988	A1	20050616	US 2005-36282		20050114

				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	US 2005176728	A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430

FAN 2004:703130

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004167201	A1	20040826	US 2004-776657		20040210
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P	20010810

FAN 2004:965987

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004224957	A1	20041111	US 2004-837519		20040430
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
	AU 2004235792	A1	20041118	AU 2004-235792		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
	WO 2004098602	A1	20041118	WO 2004-US13803		20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
EP 1622618		A1	20060208	EP 2004-751262		20040503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
BR 2004010694		A	20060620	BR 2004-10694		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
CN 1816337		A	20060809	CN 2004-80018907		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
JP 2006525369		T	20061109	JP 2006-514263		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
US 2005130988		A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
US 2005124636		A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
US 2005176728		A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219

				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2006287330	A1	20061221	US 2006-464051		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811
	US 2006287331	A1	20061221	US 2006-464053		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811
	US 2006287332	A1	20061221	US 2006-464069		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811

FAN 2005:497489

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-311404P	P	20010810
	US 2004152134	A1	20040805	US 2004-761889		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	US 2004157264	A1	20040812	US 2004-762079		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-474497P	P	20030530
	WO 2005102340	A1	20051103	WO 2004-US1462		20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-474497P	P	20030530
	US 2004224957	A1	20041111	US 2004-837519		20040430

				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

FAN 2005:527392

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

FAN 2005:735324

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005176728	A1	20050811	US 2005-99814	20050405
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419

				US 2004-837519	A2 20040430
WO 2003013571		A1	20030220	WO 2002-US25574	20020812
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
US 2004157264		A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
WO 2005102340		A1	20051103	WO 2004-US1462	20040121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
US 2004224957		A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

OS MARPAT 138:188071

GI



I

AB The invention relates to a method of deriving a peptidomimetic of a biol. active metallopeptide. The peptidomimetic contains at least one non-peptide ring structure and at least two amino acid-related elements. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5 and 6-5 bicyclic fused ring structure melanocortin receptor-specific peptidomimetics. The examples describe the synthesis of pyrrolidines, 2-piperazinones [e.g., I [R = BuCH2CH2CO-Ser(Bzl)-D-Phe(2-Cl)]], hexahydropyrrolo[1,2-a]pyrazin-4-ones, hexahydropyrrolo[1,2-a]imidazol-3-ones, 1,4-benzodiazepines, and piperazines. Competitive inhibition testing of compound I against α-MSH yielded the following results at 1 μM: melanocortin-1 receptor (MC1-R) 96%, MC3-R 51%, MC4-R 99%, and MC5-R 82%.

IT 497935-48-5P 497935-49-6P 497935-50-9P
497935-51-0P 497935-52-1P 497935-53-2P
497935-54-3P 497935-55-4P 497935-56-5P
497935-57-6P 497935-58-7P 497935-59-8P

497935-60-1P 497935-61-2P 497935-62-3P
497935-63-4P 497935-64-5P 497935-65-6P
497935-66-7P 497935-67-8P 497935-68-9P
497935-69-0P 497935-70-3P 497935-71-4P
497935-72-5P 497935-73-6P 497935-74-7P
497935-75-8P 497935-76-9P 497935-77-0P
497935-78-1P 497935-79-2P 497935-80-5P
497935-81-6P 497935-82-7P 497935-83-8P
497935-84-9P 497935-85-0P 497935-86-1P
497935-87-2P 497935-88-3P 497935-89-4P
497935-90-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptidomimetics of biol. active metallopeptides)

RN 497935-48-5 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-49-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-50-9 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-51-0 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-52-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-53-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-54-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-55-4 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-56-5 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-57-6 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-58-7 CAPLUS
CN 2-Naphthalenecarboxamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-59-8 CAPLUS
CN 1H-Indene-2-acetamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-60-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(2-naphthalenyloxy)-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-61-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-phenoxy-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-62-3 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-63-4 CAPLUS
CN 1H-Indene-2-carboxamide, 2-amino-N-[(1S)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-64-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-65-6 CAPLUS
CN 1H-Indene-1-carboxamide, 1-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-66-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-67-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-68-9 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-69-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-70-3 CAPLUS
CN Heptanamide, 7-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-71-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-3-(2-chlorophenyl)-1-oxo-2-[(phenylmethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-72-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-73-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(2-

chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-74-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-75-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-(phenoxymethyl)-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-76-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-77-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-78-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-79-2 CAPLUS
CN Heptanamide, 7-amino-N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-80-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-81-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-82-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-83-8 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-84-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-85-0 CAPLUS
CN Butanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-86-1 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-87-2 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-naphthalenyloxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-88-3 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-phenoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-89-4 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(4-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-90-7 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:961972 CAPLUS
DN 143:248665
TI Preparation of bicyclic melanocortin-specific compounds
IN Sharma, Shubh D.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh
PA Palatin Technologies, Inc., USA
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005079574	A1	20050901	WO 2004-US1505	20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004-US1505 20040121

OS MARPAT 143:248665

GI



I



Ser(Bzl)-D-Phe(4-Cl)

II

AB The invention discloses melanocortin receptor (MC-R)-specific bicyclic compds. having the structure I [R1 is L1-J, where L1 is a linker and J is a ring structure; R2 is (CH2)1-6-W, where W is a heteroarom. unit with at least one cationic center, hydrogen bond donor or acceptor in which at least one atom is N; R3 is L2-Q, where L2 is a linker and Q is (un)substituted Ph or naphthyl: X = CH2 or CO; X1 is null or CH2], or stereoisomers or pharmaceutically-acceptable salts, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors and have utility in the treatment of melanocortin receptor-related disorders and conditions. Thus, pyrroloimidazolyl peptide II was prepared and assayed for competitive binding against 128I-NDP-α-MSH (90, 14, 81 and 86% inhibition for MC1-R, MC3-R, MC4-R and MC5-R, resp., at 1 μM).

IT 497935-48-5P 497935-49-6P 497935-50-9P
497935-51-0P 497935-52-1P 497935-53-2P
497935-54-3P 497935-55-4P 497935-56-5P
497935-57-6P 497935-58-7P 497935-59-8P
497935-60-1P 497935-61-2P 497935-62-3P
497935-63-4P 497935-64-5P 497935-65-6P
497935-66-7P 497935-67-8P 497935-68-9P
497935-69-0P 497935-70-3P 497935-71-4P
497935-72-5P 497935-73-6P 497935-74-7P
497935-75-8P 497935-76-9P 497935-77-0P
497935-78-1P 497935-79-2P 497935-80-5P
497935-81-6P 497935-82-7P 497935-83-8P
497935-84-9P 497935-85-0P 497935-86-1P
497935-87-2P 497935-88-3P 497935-89-4P
497935-90-7P 728039-00-7P 728039-01-8P

728039-02-9P 728039-03-0P 728039-04-1P
728039-05-2P 728039-06-3P 728039-07-4P
728039-08-5P 728039-09-6P 728039-10-9P
728039-11-0P 728039-12-1P 728039-13-2P
728039-14-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bicyclic melanocortin receptor-specific compds. for treating eating disorders and sexual dysfunction)

RN 497935-48-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-49-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-50-9 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-51-0 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-52-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-53-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-54-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-55-4 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-56-5 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-57-6 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-58-7 CAPLUS
CN 2-Naphthalenecarboxamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-59-8 CAPLUS
CN 1H-Indene-2-acetamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-60-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(2-naphthalenyloxy)-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-61-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-phenoxy-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-62-3 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-63-4 CAPLUS
CN 1H-Indene-2-carboxamide, 2-amino-N-[(1S)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-64-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-65-6 CAPLUS
CN 1H-Indene-1-carboxamide, 1-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-66-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-67-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-68-9 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-69-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-70-3 CAPLUS
CN Heptanamide, 7-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-71-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-3-(2-chlorophenyl)-1-oxo-2-[(phenylmethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-72-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-73-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(2-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 497935-74-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-75-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-(phenoxymethyl)-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-76-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-77-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-78-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-79-2 CAPLUS
CN Heptanamide, 7-amino-N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-80-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-81-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-82-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-83-8 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-84-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-85-0 CAPLUS
CN Butanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-86-1 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-87-2 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-naphthalenyloxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-88-3 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-phenoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-89-4 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(4-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-90-7 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-00-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-01-8 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-02-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-difluorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-03-0 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-04-1 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(3-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-05-2 CAPLUS

CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-06-3 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-07-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(3,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-08-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-

[(2R)-2-amino-1-oxo-3-[4-(trifluoromethyl)phenyl]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-09-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-3-(4-methylphenyl)-1-oxopropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-10-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-11-0 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-cyanophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-12-1 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-13-2 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[[(3S,4R)-4-(4-chlorophenyl)-3-pyrrolidinyl]carbonyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-14-3 CAPLUS
CN Guanidine, [3-[(2S,5R,7aS)-1-[(2R)-2-amino-3-(2,4-dichlorophenyl)propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:527392 CAPLUS
DN 143:20084
TI Naphthalene-containing melanocortin receptor-specific small molecule
IN Sharma, Shubh D.; Shadiack, Annette M.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh; Burris, Kevin; Purma, Papireddy
PA Palatin Technologies, Inc., USA
SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 837,519.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 2005130988	A1	20050616	US 2005-36282		20050114
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-536606P	P	20040114
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
WO 2003013571	A1	20030220	WO 2002-US25574		20020812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2001-311404P	P	20010810
US 2004152134	A1	20040805	US 2004-761889		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
US 2004157264	A1	20040812	US 2004-762079		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812

				US 2003-474497P	P 20030530
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

PATENT FAMILY INFORMATION:

FAN 2003:133079

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	CA 2462200	A1	20030220	CA 2002-2462200	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	EP 1425029	A1	20040609	EP 2002-768507	20020812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	JP 2005504043	T	20050210	JP 2003-518577	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	US 2004167201	A1	20040826	US 2004-776657	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004171520	A1	20040902	US 2004-776419	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A1 20020812
	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121

				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430
	US 2005176728	A1	20050811	US 2005-99814	20050405
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430

FAN 2004:633168

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P 20010810
	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121

				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430

FAN 2004:652533

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430
	US 2005176728	A1	20050811	US 2005-99814	20050405
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405

				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430

FAN 2004:703130

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004167201	A1	20040826	US 2004-776657	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P 20010810

FAN 2004:965987

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
	AU 2004235792	A1	20041118	AU 2004-235792	20040503
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A 20040430
				WO 2004-US13803	W 20040503
	WO 2004098602	A1	20041118	WO 2004-US13803	20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A 20040430
	EP 1622618	A1	20060208	EP 2004-751262	20040503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A 20040430
				WO 2004-US13803	W 20040503
	BR 2004010694	A	20060620	BR 2004-10694	20040503
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A 20040430
				WO 2004-US13803	W 20040503
	CN 1816337	A	20060809	CN 2004-80018907	20040503
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A 20040430
				WO 2004-US13803	W 20040503

	JP 2006525369	T	20061109	JP 2006-514263		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
	US 2005130988	A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	US 2005176728	A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2006287330	A1	20061221	US 2006-464051		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811
	US 2006287331	A1	20061221	US 2006-464053		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811
	US 2006287332	A1	20061221	US 2006-464069		20060811
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
				US 2005-707488P	P	20050811

FAN 2005:497489

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121

				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

FAN 2005:735324

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005176728	A1	20050811	US 2005-99814	20050405
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810

			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
WO 2005102340	A1	20051103	WO 2004-US1462		20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2003-474497P	P	20030530
US 2004224957	A1	20041111	US 2004-837519		20040430
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219

OS MARPAT 143:20084

AB A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula I (where R1 = a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, L = a conformationally restricted ring system consisting of a single ring or bicyclic nonarom. carbocyclic ring system, etc., R2= -(CH2)4NH2,-(CH2)3NHC(NH2)=NH, etc., R3 = L-or D-isomer of Phe, Phe(4-F), Phe(4-Br), etc., and Rx = H, C-C6 aliphatic linear chain, etc.).

IT 497935-81-6P 497935-84-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(naphthalene-containing melanocortin receptor-specific small mol.)

RN 497935-81-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-84-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:633168 CAPLUS
DN 141:151030
TI Bicyclic melanocortin-specific compounds
IN Sharma, Shubh D.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh
PA Palatin Technologies, Inc., USA
SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of WO 2003 13,571.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004152134	A1	20040805	US 2004-761889		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-311404P	P	20010810
	US 2005130988	A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810

				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430

PATENT FAMILY INFORMATION:

FAN 2003:133079

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	CA 2462200	A1	20030220	CA 2002-2462200	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	EP 1425029	A1	20040609	EP 2002-768507	20020812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	JP 2005504043	T	20050210	JP 2003-518577	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	US 2004167201	A1	20040826	US 2004-776657	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004171520	A1	20040902	US 2004-776419	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A1 20020812
	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812

				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	US 2005176728	A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430

FAN 2004:652533

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004157264	A1	20040812	US 2004-762079		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-474497P	P	20030530
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P	20010810
	WO 2005102340	A1	20051103	WO 2004-US1462		20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-474497P	P	20030530
	US 2005130988	A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812

				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	US 2005176728	A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430

FAN 2004:703130

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004167201	A1	20040826	US 2004-776657		20040210
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P	20010810

FAN 2004:965987

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004224957	A1	20041111	US 2004-837519		20040430
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
	AU 2004235792	A1	20041118	AU 2004-235792		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
	WO 2004098602	A1	20041118	WO 2004-US13803		20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
	EP 1622618	A1	20060208	EP 2004-751262		20040503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
BR 2004010694	A	20060620	BR 2004-10694		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
CN 1816337	A	20060809	CN 2004-80018907		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
JP 2006525369	T	20061109	JP 2006-514263		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
US 2005130988	A1	20050616	US 2005-36282		20050114
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-536606P	P	20040114
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
US 2005124636	A1	20050609	US 2005-40838		20050121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
US 2005176728	A1	20050811	US 2005-99814		20050405
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
US 2006287330	A1	20061221	US 2006-464051		20060811
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
			US 2005-707488P	P	20050811
US 2006287331	A1	20061221	US 2006-464053		20060811
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
			US 2005-707488P	P	20050811
US 2006287332	A1	20061221	US 2006-464069		20060811

				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430
				US 2005-707488P	P 20050811

FAN 2005:497489

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

FAN 2005:527392

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219

				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2004224957	A1	20041111	US 2004-837519	20040430
				US 2003-467442P	P 20030501
				US 2004-546393P	P 20040219

FAN 2005:735324

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005176728	A1	20050811	US 2005-99814	20050405
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	US 2004157264	A1	20040812	US 2004-762079	20040121

US 2001-311404P P 20010810
WO 2002-US25574 A2 20020812
US 2003-474497P P 20030530
WO 2005102340 A1 20051103 WO 2004-US1462 20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003-474497P P 20030530
US 2004224957 A1 20041111 US 2004-837519 20040430
US 2003-467442P P 20030501
US 2004-546393P P 20040219
OS MARPAT 141:151030
GI



I

AB The invention discloses melanocortin receptor-specific bicyclic compds. having the structure I (R1 = L1-J wherein L1 is a linker and J is a ring structure selected form the group consisting of substituted or unsubstituted aromatic carboxylic rings, substituted or unsubstituted non-aromatic carboxylic rings, substituted or unsubstituted aromatic fused carbobicyclic ring groups, etc.; R2 = (CH2)y-W wherein W is a heteroarom. unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor wherein at least one atom is N; R3 = L2-Q wherein L2 is a linker and Q is an aromatic carboxylic ring selected from the group consisting of Ph, substituted Ph, naphthyl and substituted naphthyl: X = CH2 or C=O and z is 0 or 1), and stereoisomer and pharmaceutically acceptable salts thereof, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Pharmaceutical compns. containing a compound of structure I and methods relating to the use thereof for treating eating disorders and sexual dysfunction are also disclosed.

IT 497935-48-5P 497935-49-6P 497935-50-9P
497935-51-0P 497935-52-1P 497935-53-2P
497935-54-3P 497935-55-4P 497935-56-5P
497935-57-6P 497935-58-7P 497935-59-8P
497935-60-1P 497935-61-2P 497935-62-3P
497935-63-4P 497935-64-5P 497935-65-6P
497935-66-7P 497935-67-8P 497935-68-9P
497935-69-0P 497935-70-3P 497935-71-4P
497935-72-5P 497935-73-6P 497935-74-7P
497935-75-8P 497935-76-9P 497935-77-0P
497935-78-1P 497935-79-2P 497935-80-5P
497935-81-6P 497935-82-7P 497935-83-8P
497935-84-9P 497935-85-0P 497935-86-1P
497935-87-2P 497935-88-3P 497935-89-4P
497935-90-7P 728039-00-7P 728039-01-8P
728039-02-9P 728039-03-0P 728039-04-1P

728039-05-2P 728039-06-3P 728039-07-4P
728039-08-5P 728039-09-6P 728039-10-9P
728039-11-0P 728039-12-1P 728039-13-2P
728039-14-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bicyclic melanocortin receptor-specific compds. for treating disorders such as eating disorders and sexual dysfunction)

RN 497935-48-5 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-49-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-50-9 CAPLUS

CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-51-0 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-52-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-53-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-54-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-55-4 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-56-5 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-57-6 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-58-7 CAPLUS
CN 2-Naphthalenecarboxamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-59-8 CAPLUS
CN 1H-Indene-2-acetamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-60-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(2-naphthalenyloxy)-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-61-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-phenoxy-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-62-3 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-63-4 CAPLUS
CN 1H-Indene-2-carboxamide, 2-amino-N-[(1S)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-64-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-65-6 CAPLUS
CN 1H-Indene-1-carboxamide, 1-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-66-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-67-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-68-9 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-69-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-70-3 CAPLUS
CN Heptanamide, 7-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-71-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-3-(2-chlorophenyl)-1-oxo-2-[(phenylmethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-72-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-73-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(2-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 497935-74-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-75-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-(phenoxymethyl)-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-76-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-77-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-78-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-79-2 CAPLUS
CN Heptanamide, 7-amino-N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-80-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-81-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-82-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-83-8 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-84-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-85-0 CAPLUS
CN Butanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-86-1 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-87-2 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-naphthalenyloxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-88-3 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-phenoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-89-4 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(4-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-90-7 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-00-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-01-8 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-02-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-difluorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-03-0 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-04-1 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(3-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-05-2 CAPLUS

CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2-chlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-06-3 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(2,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-07-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(3,4-dichlorophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-08-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-

[(2R)-2-amino-1-oxo-3-[4-(trifluoromethyl)phenyl]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-09-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-3-(4-methylphenyl)-1-oxopropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-10-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-11-0 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 1-[(2R)-2-amino-3-(4-cyanophenyl)-1-oxopropyl]-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-12-1 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[(2R)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-13-2 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-[3-[(aminoiminomethyl)amino]propyl]-1-[[(3S,4R)-4-(4-chlorophenyl)-3-pyrrolidinyl]carbonyl]hexahydro-5-(2-naphthalenylmethyl)-, (2S,5R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728039-14-3 CAPLUS
CN Guanidine, [3-[(2S,5R,7aS)-1-[(2R)-2-amino-3-(2,4-dichlorophenyl)propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:133079 CAPLUS
DN 138:188071
TI Peptidomimetics of biologically active metallopeptides
IN Sharma, Shubh D.; Shi, Yiqun; Rajpurohit, Ramesh; Wu, Zhijun
PA Palatin Technologies, Inc., USA
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	CA 2462200	A1	20030220	CA 2002-2462200	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	EP 1425029	A1	20040609	EP 2002-768507	20020812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	JP 2005504043	T	20050210	JP 2003-518577	20020812
				US 2001-311404P	P 20010810
				WO 2002-US25574	W 20020812
	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	US 2004167201	A1	20040826	US 2004-776657	20040210
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812

US 2004171520	A1	20040902	US 2004-776419	20040210
			US 2001-311404P	P 20010810
			WO 2002-US25574	A1 20020812
US 2005130988	A1	20050616	US 2005-36282	20050114
			US 2001-311404P	P 20010810
			WO 2002-US25574	A2 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-536606P	P 20040114
			US 2004-761889	A2 20040121
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219
			US 2004-559741P	P 20040405
			US 2004-563739P	P 20040419
			US 2004-837519	A2 20040430
US 2005124636	A1	20050609	US 2005-40838	20050121
			US 2001-311404P	P 20010810
			WO 2002-US25574	A2 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-538100P	P 20040121
			US 2004-761889	A2 20040121
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219
			US 2004-837519	A2 20040430
US 2005176728	A1	20050811	US 2005-99814	20050405
			US 2001-311404P	P 20010810
			WO 2002-US25574	A2 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219
			US 2004-559741P	P 20040405
			US 2004-563739P	P 20040419
			US 2004-837519	A2 20040430

PATENT FAMILY INFORMATION:

FAN 2004:633168

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004152134	A1	20040805	US 2004-761889	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-311404P	P 20010810
US 2005130988	A1	20050616	US 2005-36282	20050114
			US 2001-311404P	P 20010810
			WO 2002-US25574	A2 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-536606P	P 20040114
			US 2004-761889	A2 20040121
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219

				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-837519	A2 20040430

FAN 2004:652533

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157264	A1	20040812	US 2004-762079	20040121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-474497P	P 20030530
	WO 2003013571	A1	20030220	WO 2002-US25574	20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-311404P	P 20010810
	WO 2005102340	A1	20051103	WO 2004-US1462	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-474497P	P 20030530
	US 2005130988	A1	20050616	US 2005-36282	20050114
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-536606P	P 20040114
				US 2004-761889	A2 20040121
				US 2004-762079	A2 20040121
				US 2004-546393P	P 20040219
				US 2004-559741P	P 20040405
				US 2004-563739P	P 20040419
				US 2004-837519	A2 20040430
	US 2005124636	A1	20050609	US 2005-40838	20050121
				US 2001-311404P	P 20010810
				WO 2002-US25574	A2 20020812
				US 2003-467442P	P 20030501
				US 2003-474497P	P 20030530
				US 2004-538100P	P 20040121
				US 2004-761889	A2 20040121

				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	US 2005176728	A1	20050811	US 2005-99814		20050405
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430

FAN 2004:703130

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004167201	A1	20040826	US 2004-776657		20040210
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-311404P	P	20010810

FAN 2004:965987

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004224957	A1	20041111	US 2004-837519		20040430
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
	AU 2004235792	A1	20041118	AU 2004-235792		20040503
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
				WO 2004-US13803	W	20040503
	WO 2004098602	A1	20041118	WO 2004-US13803		20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430
	EP 1622618	A1	20060208	EP 2004-751262		20040503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219
				US 2004-837519	A	20040430

			WO 2004-US13803	W	20040503
BR 2004010694	A	20060620	BR 2004-10694		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
CN 1816337	A	20060809	CN 2004-80018907		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
JP 2006525369	T	20061109	JP 2006-514263		20040503
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
US 2005130988	A1	20050616	US 2005-36282		20050114
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-536606P	P	20040114
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
US 2005124636	A1	20050609	US 2005-40838		20050121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
US 2005176728	A1	20050811	US 2005-99814		20050405
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
US 2006287330	A1	20061221	US 2006-464051		20060811
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
			US 2005-707488P	P	20050811
US 2006287331	A1	20061221	US 2006-464053		20060811
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
			US 2005-707488P	P	20050811
US 2006287332	A1	20061221	US 2006-464069		20060811
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430
			US 2005-707488P	P	20050811

FAN 2005:497489

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2005124636	A1	20050609	US 2005-40838		20050121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-538100P	P	20040121
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-837519	A2	20040430
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-311404P	P	20010810
	US 2004152134	A1	20040805	US 2004-761889		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
	US 2004157264	A1	20040812	US 2004-762079		20040121
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-474497P	P	20030530
	WO 2005102340	A1	20051103	WO 2004-US1462		20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-474497P	P	20030530
	US 2004224957	A1	20041111	US 2004-837519		20040430
				US 2003-467442P	P	20030501
				US 2004-546393P	P	20040219

FAN 2005:527392

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2005130988	A1	20050616	US 2005-36282		20050114
				US 2001-311404P	P	20010810
				WO 2002-US25574	A2	20020812
				US 2003-467442P	P	20030501
				US 2003-474497P	P	20030530
				US 2004-536606P	P	20040114
				US 2004-761889	A2	20040121
				US 2004-762079	A2	20040121
				US 2004-546393P	P	20040219
				US 2004-559741P	P	20040405
				US 2004-563739P	P	20040419
				US 2004-837519	A2	20040430
	WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-311404P	P	20010810
US 2004152134	A1	20040805	US 2004-761889		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
US 2004157264	A1	20040812	US 2004-762079		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
WO 2005102340	A1	20051103	WO 2004-US1462		20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2003-474497P	P	20030530
US 2004224957	A1	20041111	US 2004-837519		20040430
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219

FAN 2005:735324

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 2005176728	A1	20050811	US 2005-99814		20050405
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
WO 2003013571	A1	20030220	WO 2002-US25574		20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-311404P	P	20010810
US 2004157264	A1	20040812	US 2004-762079		20040121
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
WO 2005102340	A1	20051103	WO 2004-US1462		20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2003-474497P	P	20030530
US 2004224957	A1	20041111	US 2004-837519		20040430
			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219

OS MARPAT 138:188071

GI



I

AB The invention relates to a method of deriving a peptidomimetic of a biol. active metallopeptide. The peptidomimetic contains at least one non-peptide ring structure and at least two amino acid-related elements. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5 and 6-5 bicyclic fused ring structure melanocortin receptor-specific peptidomimetics. The examples describe the synthesis of pyrrolidines, 2-piperazinones [e.g., I [R = BuCH2CH2CO-Ser(Bzl)-D-Phe(2-Cl)]], hexahydropyrrolo[1,2-a]pyrazin-4-ones, hexahydropyrrolo[1,2-a]imidazol-3-ones, 1,4-benzodiazepines, and piperazines. Competitive inhibition testing of compound I against α-MSH yielded the following results at 1 μM: melanocortin-1 receptor (MC1-R) 96%, MC3-R 51%, MC4-R 99%, and MC5-R 82%.

IT 497935-48-5P 497935-49-6P 497935-50-9P
497935-51-0P 497935-52-1P 497935-53-2P
497935-54-3P 497935-55-4P 497935-56-5P
497935-57-6P 497935-58-7P 497935-59-8P
497935-60-1P 497935-61-2P 497935-62-3P
497935-63-4P 497935-64-5P 497935-65-6P
497935-66-7P 497935-67-8P 497935-68-9P
497935-69-0P 497935-70-3P 497935-71-4P
497935-72-5P 497935-73-6P 497935-74-7P
497935-75-8P 497935-76-9P 497935-77-0P
497935-78-1P 497935-79-2P 497935-80-5P
497935-81-6P 497935-82-7P 497935-83-8P
497935-84-9P 497935-85-0P 497935-86-1P
497935-87-2P 497935-88-3P 497935-89-4P
497935-90-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptidomimetics of biol. active metallopeptides)

RN 497935-48-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-

chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-49-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-50-9 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-51-0 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-52-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-53-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-54-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-55-4 CAPLUS
CN Heptanamide, N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-56-5 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-57-6 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-58-7 CAPLUS
CN 2-Naphthalenecarboxamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-59-8 CAPLUS
CN 1H-Indene-2-acetamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-60-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(2-naphthalenyloxy)-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-61-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-phenoxy-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-62-3 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-63-4 CAPLUS
CN 1H-Indene-2-carboxamide, 2-amino-N-[(1S)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-64-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-65-6 CAPLUS
CN 1H-Indene-1-carboxamide, 1-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-66-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-67-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-68-9 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-69-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-70-3 CAPLUS
CN Heptanamide, 7-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2-chlorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-71-4 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-3-(2-chlorophenyl)-1-oxo-2-[(phenylmethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-72-5 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(4-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-73-6 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-3-(2-chlorophenyl)-1-oxopropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 497935-74-7 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-(phenoxymethyl)-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-75-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-(phenoxymethyl)-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-76-9 CAPLUS
CN 3H-Pyrrolo[1,2-a]imidazol-3-one, 2-(4-aminobutyl)-1-[(2R)-2-amino-1-oxo-3-phenylpropyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-, (2S,5R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-77-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-78-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-79-2 CAPLUS
CN Heptanamide, 7-amino-N-[(1S)-2-[[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-3-oxo-5-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-80-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-2-oxo-1-(phenylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-81-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-82-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-83-8 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-3-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-84-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-5-phenyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-85-0 CAPLUS
CN Butanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-86-1 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1R)-2-[(2S,5R,7aR)-2-[3-[(aminoiminomethyl)amino]propyl]hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(2,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-87-2 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-naphthalenyloxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-88-3 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-phenoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-89-4 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(4-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 497935-90-7 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(2S,5R,7aR)-2-(4-aminobutyl)hexahydro-5-[(2-naphthalenyloxy)methyl]-3-oxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-3-(2-chlorophenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:962180 CAPLUS
DN 138:170390
TI Total Synthesis of (-)-Fumiquinazolines A, B, C, E, H, and I. Approaches to the Synthesis of Fiscalin A
AU Snider, Barry B.; Zeng, Hongbo
CS Department of Chemistry, Brandeis University, Waltham, MA, 02454-9110, USA
SO Journal of Organic Chemistry (2003), 68(2), 545-563
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:170390
GI



I II

AB The first syntheses of (-)-fumiquinazolines A, B, and I, which proceed in 14 steps from protected tryptophan, anthranilic acid, leucine, and alanine in 7% overall yield, are described. Tricycle I (R = Me, CH2CHMe2) was formed by a palladium-catalyzed cyclization. Oxidation of I (R = Me) with a saccharine-derived oxaziridine for fumiquinazolines A and B and oxidation of I (r = CH2CHMe2) with dimethyldioxirane for fumiquinazoline I selectively formed the appropriate imidazoindolone stereoisomers. Application of the Ganesan-Mazurkiewicz cyclization completed the syntheses. Efficient 14-step syntheses of (-)-fumiquinazolines C and E and a 15-step synthesis of (-)-fumiquinazoline H using FmocNHCH(CH2SePh)CO2H as a dehydroalanine

precursor that spontaneously eliminated benzeneselenol without oxidation under the cyclization conditions are also reported. Model II for fiscalin A with the H and OH anti to each other has been prepared, but the procedure that worked for the model failed with the fully functionalized side chain.

IT 210702-36-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(total synthesis of (-)-fumiquinazolines A, B, C, E, H, and I and fiscalin A via Ganesan-Mazurkiewicz cyclization)

RN 210702-36-6 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2,9-dimethyl-3-oxo-, phenylmethyl ester, (2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 316828-38-3P 316828-43-0P 316828-44-1P
316828-45-2P 316828-53-2P 316828-54-3P
316828-55-4P 316828-57-6P 422319-31-1P
422319-35-5P 422319-37-7P 422319-39-9P
422319-40-2P 422319-50-4P 496962-01-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total synthesis of (-)-fumiquinazolines A, B, C, E, H, and I and fiscalin A via Ganesan-Mazurkiewicz cyclization)

RN 316828-38-3 CAPLUS

CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-43-0 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-

(2-methylpropyl)-3-oxo-9-[[(1S,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 316828-44-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-45-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-53-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1S,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 316828-54-3 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 316828-55-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1S,4S)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 316828-57-6 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4S)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 422319-31-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-35-5 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4R)-1,3,4,6-tetrahydro-1-methoxy-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-37-7 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 422319-39-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R,9aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 422319-40-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-50-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 496962-01-7 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9a-methoxy-2,9-dimethyl-3-oxo-9-[(triethylsilyl)oxy]-, phenylmethyl ester, (2S,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 316828-37-2P 422319-55-9P 496962-04-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of (-)-fumiquinazolines A, B, C, E, H, and I and fiscalin A via Ganesan-Mazurkiewicz cyclization)
RN 316828-37-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422319-55-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 496962-04-0 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9a-methoxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-9-[(triethylsilyl)oxy]-, methyl ester, (αR,2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:177405 CAPLUS
DN 136:369882
TI Total Syntheses of (-)-Fumiquinazolines C, E, and H
AU Snider, Barry B.; Zeng, Hongbo
CS Department of Chemistry, Brandeis University, Waltham, MA, 02454-9110, USA
SO Organic Letters (2002), 4(7), 1087-1090
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:369882
AB Total syntheses of the heptacyclic fumiquinazolines C and H have been accomplished efficiently using FmocNHCH(CH2SePh)CO2H as the precursor for the requisite dehydrofumiquinazoline.
IT 422319-31-1P 422319-35-5P 422319-37-7P
422319-39-9P 422319-40-2P 422319-50-4P
422319-55-9P 422319-66-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total syntheses of (-)-fumiquinazolines C, E, and H)
RN 422319-31-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-35-5 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4R)-1,3,4,6-tetrahydro-1-methoxy-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-37-7 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 422319-39-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R,9aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 422319-40-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 422319-50-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(4R)-1,3,4,6-tetrahydro-1-methylene-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 422319-55-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 422319-66-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:818613 CAPLUS
DN 134:86414
TI Total Syntheses of (-)-Fumiquinazolines A, B, and I
AU Snider, Barry B.; Zeng, Hongbo
CS Department of Chemistry MS015, Brandeis University, Waltham, MA, 02454-9110, USA
SO Organic Letters (2000), 2(25), 4103-4106
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 134:86414
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The first total syntheses of (-)-fumiquinazolines A (I α-Me, α-OH, R = β-Me), B (I β-Me, α-OH, R = β-Me), and I (I α-Me, β-OH, R = β-i-Bu) have been accomplished efficiently using the Pd-catalyzed cyclization of an iodoindole carbamate II (R = Me, i-Bu) to construct the imidazoindolone moiety III (R = Me, i-Bu) and the dehydrative cyclization of a diamide followed by rearrangement through an amidine to construct the quinazolone moiety.

IT 316828-38-3P 316828-43-0P 316828-44-1P
316828-45-2P 316828-53-2P 316828-54-3P
316828-55-4P 316828-57-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total syntheses of (-)-fumiquinazolines A, B, and I)

RN 316828-38-3 CAPLUS

CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-43-0 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(1S,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 316828-44-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-45-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-methyl-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316828-53-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1S,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 316828-54-3 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4R)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 316828-55-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1S,4S)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 316828-57-6 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-methyl-3-oxo-9-[[(1R,4S)-1,3,4,6-tetrahydro-1-methyl-3,6-dioxo-2H-pyrazino[2,1-b]quinazolin-4-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





IT 316828-37-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total syntheses of (-)-fumiquinazolines A, B, and I)
RN 316828-37-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-9-propanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-α-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, methyl ester, (αR,2S,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:411058 CAPLUS
DN 129:136341
TI Total Syntheses of (-)-Asperlicin and (-)-Asperlicin C
AU He, Feng; Foxman, Bruce M.; Snider, Barry B.
CS Department of Chemistry, Brandeis University, Waltham, MA, 02254-9110, USA
SO Journal of the American Chemical Society (1998), 120(25), 6417-6418
CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society
DT Journal
LA English
OS CASREACT 129:136341
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB (-)-Asperlicin (I) was prepared from Nα-(2,2,2-trichloroethoxycarbonyl)-L-tryptophan and N-(benzyloxycarbonyl)-L-leucine via cyclization of indoloimidazole II with o-[(2,2,2-trichloroethoxycarbonyl)amino]benzoic acid and cyclocondensation of benzodiazepinedione III with o-azidobenzoyl chloride. (-)-Asperlicin C (IV) was prepared via a similar cyclocondensation with o-azidobenzoyl chloride.

IT 102743-51-1P 210702-36-6P 210702-37-7P
210702-38-8P 210702-40-2P 210702-50-4P
210702-56-0P 210702-57-1P 210702-58-2P
210702-60-6P 210702-62-8P 210704-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total syntheses of (-)-asperlicin and (-)-asperlicin C)

RN 102743-51-1 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(7S)-5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 210702-36-6 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2,9-dimethyl-3-oxo-, phenylmethyl ester, (2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210702-37-7 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2,9-dimethyl-3-oxo-, phenylmethyl ester, (2S,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210702-38-8 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2,9-dimethyl-3-oxo-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 210702-40-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2,9-dimethyl-3-oxo-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210702-50-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 9-[[(7S,7aS)-5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210702-56-0 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-9-methyl-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210702-57-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-9-methyl-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210702-58-2 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9-methyl-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 210702-60-6 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 9-[[(7S,7aS)-5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-2,3,9,9a-tetrahydro-9-hydroxy-9a-methoxy-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210702-62-8 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 9-[[(7S,7aS)-5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210704-04-4 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-9-methyl-2-(2-methylpropyl)-3-oxo-, phenylmethyl ester, (2S,9R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:104822 CAPLUS
DN 122:56541
TI Anodic amide oxidations: conformationally restricted peptide building blocks from the direct oxidation of dipeptides
AU Cornille, Fabrice; Fobian, Yvetter M.; Slomczynska, Urszula; Beusen, Denise D.; Marshall, Garland R.; Moeller, Kevin D.
CS Dep. Mol. Biol. Pharmacol., Washington Univ., St. Louis, MO, 63130, USA
SO Tetrahedron Letters (1994), 35(38), 6989-92
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 122:56541
GI



I



II

AB A pair of bicyclic lactam based conformationally restricted peptide mimetics I (R 1 = H, R2 = CO2Me; R1 = CO2Me, R2 = H) have been synthesized in good yield by the direct anodic oxidation of dipeptides Boc-L-Hse-D-Pro-OMe and Boc-L-Hse-L-Pro-OMe. Similarly, bicyclic product II was obtained in 56% overall yield in a 2-step oxidation-cyclization procedure starting with dipeptide Boc-L-Ala-L-Pro-OMe.. This work highlights the simplicity of using electrochem. to construct peptide mimetics and serves to further define the nature of the substituent that are compatible with an electrochem. procedure for annulating rings into amino acid derivs.

IT 159912-49-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of conformationally restricted peptide building blocks via direct anodic oxidation and cyclization of proline-containing dipeptides)

RN 159912-49-9 CAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-2-methyl-3-oxo-, 1-(1,1-dimethylethyl) 5-methyl ester, [2S-(2α,5β,7aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:46800 CAPLUS

DN 122:10558

TI Application of HMBC and HMQC-TOCSY NMR methods to assign the structures of bicyclic-peptide mimetics

AU d'Avignon, D. Andre; Hanau, Cathleen E.; Fobian, Yvette M.; Moeller, Kevin D.

CS Department of Chemistry, Washington University, St. Louis, MO, 63130, USA

SO Journal of Coordination Chemistry (1994), 32(1-3), 135-44
CODEN: JCCMBQ; ISSN: 0095-8972

DT Journal

LA English

AB The structures of representative bicyclic peptides are confirmed through the NMR methods of HMBC and HMQC-TOCSY. Complete assignment of proton and carbon resonances is afforded by these two-dimensional NMR methods. HMQC-TOCSY is especially useful for assigning spectra in mols. having extensive proton spin systems and in establishing connectivities between protonated carbons. Long-range proton-carbon connectivities obtained by HMBC confirm

structure in mols. containing heteroatoms or non-protonated carbons that interrupt proton spin systems.

IT 159326-38-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(application of HMBC and HMQC-TOCSY NMR methods to assign the structures of bicyclic peptide mimetics)

RN 159326-38-2 CAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-2-methyl-3-oxo-, 1-(1,1-dimethylethyl) 5-methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:473065 CAPLUS

DN 119:73065

TI Synthesis of a bicyclic γ-lactam dipeptide analog

AU Baldwin, Jack E.; Hulme, Christopher; Edwards, Alison J.; Schofield, Christopher J.; Parkes, Kevin E. B.

CS Dyson Perrins Lab., Oxford, OX1 3QY, UK

SO Tetrahedron Letters (1993), 34(10), 1665-8
CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

OS CASREACT 119:73065

GI



I

AB The synthesis of conformationally restrained bicyclic γ-lactam dipeptide mimetics I (R = H, Z, R1 = OH, OCH2Ph, NHCH2CHMe2; Z = PhCH2O2C), involving a diastereoselective bicyclization reaction is described. Thus, oxidative cleavage (OsO4, NaIO4) of dipeptide Z-L-Phe-L-NHCH(CO2CH2Ph)CH2CH2CH:X (II; X = CH2) gave aldehyde II (X = O) as a mixture of the free aldehyde and cyclic hemiaminal forms. Cyclization of this mixture with acid gave bicyclic lactam I (R = Z, R1 = OCH2Ph). The stereochem. at C-5 was determined by MO calcns. on models and by x-ray crystallog. of I (R = Z, R1 = OH). I exist as ca. 1:1 mixts of conformers at ambient temperature

IT 148696-59-7 148766-59-0
RL: PRP (Properties)
(conformation and steric energy of, vs. diastereomer, by MO calcns.)

RN 148696-59-7 CAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-2-methyl-3-oxo-, dimethyl ester, [2S-(2α,5β,7aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148766-59-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-2-methyl-3-oxo-, dimethyl ester, [2S-(2α,5β,7aα)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 148696-56-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, amidation, crystal structure, and conformation of, by NMR)
RN 148696-56-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-3-oxo-2-(phenylmethyl)-, 1-(phenylmethyl) ester, [2S-(2α,5β,7aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 148696-57-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deprotection, and conformation of, by NMR)
RN 148696-57-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-1-carboxylic acid, hexahydro-5-[[(2-methylpropyl)amino]carbonyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [2S-(2α,5β,7aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 148696-49-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, saponification, and conformation of, by NMR)
RN 148696-49-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-1,5-dicarboxylic acid, hexahydro-3-oxo-2-(phenylmethyl)-, bis(phenylmethyl) ester, [2S-(2α,5β,7aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:626158 CAPLUS
DN 105:226158
TI Cholecystokinin antagonists. Synthesis of asperlicin analogs with improved potency and water solubility
AU Bock, Mark G.; DiPardo, Robert M.; Rittle, Kenneth E.; Evans, Ben E.; Freidinger, Roger M.; Veber, Daniel F.; Chang, Raymond S. L.; Chen, Tsing Bau; Keegan, Maureen E.; Lotti, Victor J.
CS Dep. Med. Chem., Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (1986), 29(10), 1941-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 105:226158
GI



I

AB Seventeen analogs I [R = H, COCH2CH2CO2CH2Ph, COCH2CH2CO2H; R1 = H, Ac, Et, (CH2)3Ph, protected amino acid, COCH2CH2CO2H; R2 = R3 = H; R2R3 = bond] of the selective, competitive cholecystokinin (II) antagonist asperlicin (I, R = R1 = H, R2R3 = bond) were prepared These compds. were tested as inhibitors of the binding of [125I]-II to rat pancreas and guinea pig brain receptors. I [R = R2 = R3 = H, R1 = H, Et, (CH2)3Ph] were more potent than asperlicin on the pancreatic II receptor. I [R = R2 = R3 = H, R1 = COCH2CH2CO2Na] displayed potency equivalent to asperlicin on the pancreas II receptor and showed a marked improvement in water solubility, thereby facilitating the use of this class of II antagonists in physiol. and pharmacol. studies.

IT 102743-49-7P 102743-52-2P 102743-57-7P
102996-16-7P 102996-17-8P 102996-18-9P
103241-32-3P 103241-34-5P 103303-32-8P
103303-33-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cholecystokinin antagonist activity of)

RN 102743-49-7 CAPLUS

CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 7-[[1-acetyl-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]-6,7-dihydro-, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)





RN 102743-52-2 CAPLUS
CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 6,7,7a,8-tetrahydro-7-[[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1-(3-phenylpropyl)-1H-imidazo[1,2-a]indol-9-yl]methyl]-, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102743-57-7 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102996-16-7 CAPLUS
CN 3H-Imidazo[1,2-a]indol-3-one, 1-(2,6-diamino-1-oxohexyl)-1,2,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, dihydrochloride, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)



● 2 HCl

RN 102996-17-8 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-γ,3-dioxo-, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102996-18-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-γ,3-dioxo-, monosodium salt, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 103241-32-3 CAPLUS
CN Carbamic acid, [1-[(4-hydroxyphenyl)methyl]-2-[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103241-34-5 CAPLUS
CN Butanedioic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-1H-imidazo[1,2-a]indol-9-yl phenylmethyl ester, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 103303-32-8 CAPLUS
CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 7-[[1-ethyl-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]-6,7,7a,8-tetrahydro-, [2S-[2α,9β,9(7R*,7aR*),9a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103303-33-9 CAPLUS
CN 3H-Imidazo[1,2-a]indol-3-one, 1-(2,6-diamino-1-oxohexyl)-1,2,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)



IT 102743-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, acylation, and cholecystokinin antagonist activity of)
RN 102743-51-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(7S)-5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 103241-31-2P 103241-33-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation, debenzylation, and cholecystokinin antagonist activity of)

RN 103241-31-2 CAPLUS

CN Carbamic acid, [1-[[4-(phenylmethoxy)phenyl]methyl]-2-[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103241-33-4 CAPLUS

CN Butanedioic acid, phenylmethyl 2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-9-yl ester, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A









IT 102743-57-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deblocking, and cholecystokinin antagonist activity of)
RN 102743-57-7 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 102743-56-6P 102996-15-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, reduction, and cholecystokinin antagonist activity of)
RN 102743-56-6 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102996-15-6 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-1-(2-methylpropyl)-γ,3-dioxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:442854 CAPLUS
DN 105:42854
TI Quinazolinobenzodiazepinedione derivatives
IN Bock, Mark G.; Freidinger, Roger M.; Evans, Ben E.
PA Merck and Co., Inc. , USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4559338	A	19851217	US 1985-695117	19850125
	EP 190587	A1	19860813	EP 1986-100620	19860118
	R: CH, DE, FR, GB, IT, LI, NL				
				US 1985-695117 A	19850125

JP 61176594 A 19860808 JP 1986-12274 19860124
US 1985-695117 A 19850125

OS MARPAT 105:42854

GI



I

AB Title compds. I (R1, R2, and R5 are H, Br, Cl, F, OH, alkoxy, alkyl; R3 = H, carboxyalkanoyl, aminoalkanoyl, etc.; R4 = H, alkyl, alkylthioalkyl, etc.; R6 = H, R3) were prepared, and they showed their usefulness as antagonists for cholecystokinins. Also prepared were 7a,8-dihydro derivs. of I. I (R1 = R2 = R3 = R4 = R5 = R6 = H) was treated with succinic anhydride and 4-(dimethylamino)pyridine to give I (R3 = COCH2CH2CO2H, R1 = R2 = R4 = R5 = R6 = H).

IT 103022-89-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)

RN 103022-89-5 CAPLUS

CN Carbamic acid, [5-[[(1,1-dimethylethoxy)carbonyl]amino]-6-oxo-6-[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]hexyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 103066-42-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and selective deprotection of)
RN 103066-42-8 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxo-5-[2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 102743-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and O-acylation of, by succinic acid monoester)
RN 102743-51-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(7S)-5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 102996-15-6P 102996-16-7P 102996-17-8P
102996-18-9P 102996-19-0P 102996-20-3P
102996-21-4P 103066-41-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin antagonist)
RN 102996-15-6 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-1-(2-methylpropyl)-γ,3-dioxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102996-16-7 CAPLUS
CN 3H-Imidazo[1,2-a]indol-3-one, 1-(2,6-diamino-1-oxohexyl)-1,2,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, dihydrochloride, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)



● 2 HCl

RN 102996-17-8 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-γ,3-dioxo-, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102996-18-9 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-γ,3-dioxo-, monosodium salt, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 102996-19-0 CAPLUS
CN Carbamic acid, [4-amino-5-[9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 102996-20-3 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-acetic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 102996-21-4 CAPLUS

CN 1H-Imidazo[1,2-a]indole-1-acetic acid, 9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 103066-41-7 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-butanoic acid, 2,3,9,9a-tetrahydro-9-hydroxy-1-(2-methylpropyl)-γ,3-dioxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-, monosodium salt, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





● Na

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:435621 CAPLUS
DN 105:35621
TI Quinazolino-1,4-benzodiazepine-5,13-diones
IN Bock, Mark G.; Freidinger, Roger M.; Evans, Ben E.; Hartman, George D.
PA Merck and Co., Inc. , USA
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 4563451	A	19860107	US 1985-695108		19850125
	EP 189802	A1	19860806	EP 1986-100636		19860118
	R: CH, DE, FR, GB, IT, LI, NL					
				US 1985-695108	A	19850125
	JP 61176595	A	19860808	JP 1986-12276		19860124
				US 1985-695108	A	19850125

OS MARPAT 105:35621
GI



I

AB Quinazolino-1,4-benzodiazepine-5,13-diones I (X1-X3 = H, Br, Cl, F, OH, C1-4 alkyl, C1-4 alkoxy, C2-5 alkanoyl; R = H, OH, Et, substituted Ph, etc.; R1 = H, CH2CHMe2), useful as cholecystokinin (CCK) antagonists in the treatment and prevention of disorders of the gastrointestinal, central nervous, and appetite-regulatory systems of mammals, are prepared from compds. produced by aerobic fermentation of Aspergillus alliaceus. The anti-CCK activity of 11 prepared compds. was tested using the pancreas CCK receptor-binding method and the IC50 (μM) for each is reported. Thus, 268 mg 7β-[[2,3,9,9aα-tetrahydro-9α-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]quinazolino[3,2-a]-1,4-benzodiazepine-5,13(6H,7H)-dione was reacted overnight with Ac2O to yield 50 mg 7-[[1-acetyl-2,3,9,9aα-tetrahydro-9α-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]quinazolino[3,2-a]-1,4-benzodiazepine-5,13(6H,7H)-dione.

IT 102743-49-7P 102743-50-0P 102743-51-1P
102743-52-2P 102743-53-3P 102743-54-4P
102743-55-5P 102743-56-6P 102743-57-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin antagonist)

RN 102743-49-7 CAPLUS

CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 7-[[1-acetyl-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]-6,7-dihydro-, [2S-[2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)





RN 102743-50-0 CAPLUS
CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 7-[[1-ethyl-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-9-yl]methyl]-6,7,7a,8-tetrahydro- (9CI) (CA INDEX NAME)





RN 102743-51-1 CAPLUS
CN 1H-Imidazo[1,2-a]indole-1-carboxylic acid, 2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[[(7S)-5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-, phenylmethyl ester, (2S,9S,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 102743-52-2 CAPLUS
CN Quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione, 6,7,7a,8-tetrahydro-7-[[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1-(3-phenylpropyl)-1H-imidazo[1,2-a]indol-9-yl]methyl]-, [2S-[2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102743-53-3 CAPLUS
CN Carbamic acid, [2-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-2-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 102743-54-4 CAPLUS
CN Carbamic acid, [2-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 102743-55-5 CAPLUS
CN Carbamic acid, [5-[[(1,1-dimethylethoxy)carbonyl]amino]-6-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-6-oxohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 102743-56-6 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(R*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102743-57-7 CAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[9-[(5,6,7,7a,8,13-hexahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]-2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo[1,2-a]indol-1-yl]-5-oxopentyl]-, phenylmethyl ester, [2S-[1(R*),2α,9β,9(7R*,7aR*),9aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> fil medline biosis caplus scisearch embase wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                   106.49      274.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                   -11.25      -11.25

FILE 'MEDLINE' ENTERED AT 18:19:57 ON 22 DEC 2006

FILE 'BIOSIS' ENTERED AT 18:19:57 ON 22 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 18:19:57 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 18:19:57 ON 22 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 18:19:57 ON 22 DEC 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:19:57 ON 22 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> e shubh sharma/au
E1            2     SHUBEVSKA S/AU
E2            1     SHUBEYEV I/AU
E3            0 --> SHUBH SHARMA/AU
E4           13     SHUBHA/AU
E5            1     SHUBHA A B/AU
E6            5     SHUBHA B K/AU
E7           10     SHUBHA B S/AU
E8            5     SHUBHA G/AU
E9            2     SHUBHA G N/AU
E10           2     SHUBHA J P/AU
E11          12     SHUBHA K/AU
E12          12     SHUBHA K P/AU
```

```
=> e shubh s?/au
E1            2     SHUBEVSKA S/AU
E2            1     SHUBEYEV I/AU
E3            0 --> SHUBH S?/AU
E4           13     SHUBHA/AU
E5            1     SHUBHA A B/AU
E6            5     SHUBHA B K/AU
E7           10     SHUBHA B S/AU
E8            5     SHUBHA G/AU
E9            2     SHUBHA G N/AU
E10           2     SHUBHA J P/AU
E11          12     SHUBHA K/AU
E12          12     SHUBHA K P/AU

=> e sharma shubh?/au
E1            2     SHARMA SHUBH DEV/AU
E2            3     SHARMA SHUBH S/AU
E3            0 --> SHARMA SHUBH?/AU
E4           15     SHARMA SHUBHADA/AU
E5            3     SHARMA SHUBHANGNA/AU
E6            1     SHARMA SHUBHARA/AU
E7            8     SHARMA SHUBHRA/AU
E8            1     SHARMA SHUBRA/AU
E9            9     SHARMA SHUKRITI/AU
E10           1     SHARMA SHUNIL/AU
E11           1     SHARMA SHUSHIL/AU
E12           1     SHARMA SHUSHIL K/AU

=> e1-38
'E38' NOT FOUND
The E# entered is not currently defined.

=> e1-e8
L5          130 ("SHARMA SHUBH DEV"/AU OR "SHARMA SHUBH S"/AU OR "SHARMA SHUBH?"
                /AU OR "SHARMA SHUBHADA"/AU OR "SHARMA SHUBHANGNA"/AU OR "SHARMA
                SHUBHARA"/AU OR "SHARMA SHUBHRA"/AU OR "SHARMA SHUBRA"/AU)

=> melan? and l5
L6           70 MELAN? AND L5

=> dub rem l6
MISSING OPERATOR REM L6
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           55 DUP REM L6 (15 DUPLICATES REMOVED)

=> t ti l7

L7   ANSWER 1 OF 55  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
TI   Melanocortin metallopeptide constructs, combinatorial libraries
     and applications.


=> t ti l7 1-55

L7   ANSWER 1 OF 55  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
TI   Melanocortin metallopeptide constructs, combinatorial libraries
     and applications.

L7   ANSWER 2 OF 55  CAPLUS  COPYRIGHT 2006 ACS on STN
```

TI Cyclic peptide melanocortin-4 receptor antagonists for the treatment of cachexia and other disorders

L7 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cyclic peptide melanocortin-4 receptor antagonists for the treatment of cachexia and other disorders

L7 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of bicyclic melanocortin-specific compounds

L7 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI α-MSH-, γ-MSH-, and bombesin-derived metallopeptide compounds

L7 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Phosphodiesterase V inhibitor combination with melanocortin 3 and/or 4 receptor agonist for treatment of sexual dysfunction

L7 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Substituted melanocortin receptor-specific piperazine compounds

L7 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Metallopeptide compositions for treatment of sexual dysfunction

L7 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Naphthalene-containing melanocortin receptor-specific small molecule

L7 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of thieno[2,3-d]pyrimidine-2,4-diones as melanocortin receptor modulators

L7 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Identification of target-specific folding sites in proteins using metallopeptide derivatives of sequences of interest

L7 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanocortin metallopeptide constructs, combinatorial libraries, and therapeutic applications

L7 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs

L7 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Peptide composition for treatment of sexual dysfunction

L7 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of piperazine melanocortin receptor-specific compounds

L7 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of pyrrolidine melanocortin-specific compounds

L7 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of piperazines as melanocortin-specific agonists, antagonists, or mixed agonists and antagonists.

L7 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Bicyclic melanocortin-specific compounds

L7 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cyclic peptide compositions and methods for treatment of sexual

dysfunction

L7 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Peptidomimetics of biologically active metallopeptides

L7 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Linear and cyclic melanocortin receptor-specific peptides, and therapeutic use

L7 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanocortin-4 receptor selective small molecules

L7 ANSWER 23 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Melanocortin-4 receptor selective small molecules.

L7 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Identification of target-specific folding sites in peptides and proteins

L7 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanocortin metallopeptides for treatment of sexual dysfunction

L7 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Conformationally-restricted N-alkylated amino acid analogs of MT-II to probe the message sequence of α- melanotropin

L7 ANSWER 27 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Conformationally restricted N-alkylated amino acid analogs of MT-II to probe the message sequence of alpha-melanotropin.

L7 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanocortin metallopeptide constructs, combinatorial libraries, and applications

L7 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Metallopeptide combinatorial libraries synthesis and applications

L7 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Structurally determined metallo-constructs peptides as imaging and diagnostic and radiotherapeutic agents

L7 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of peptides having potent antagonist and agonist bioactivities at melanocortin receptors

L7 ANSWER 32 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 1
TI Prevention of reflex natriuresis after acute unilateral nephrectomy by melanocortin receptor antagonists.

L7 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation and biological activity of cyclic bridged α-MSH analogs

L7 ANSWER 34 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 2
TI Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c(Asp-His-Phe-Arg-Trp-Ala-Lys)-NH-2, on human melanocortin receptors.

L7 ANSWER 35 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 3
TI Selectivity of cyclic (D-Nal-7) and (D-Phe-7) substituted MSH analogues

for the melanocortin receptor subtypes.

L7 ANSWER 36 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 4
TI Characterisation of D117A and H260A mutations in the melanocortin 1 receptor.

L7 ANSWER 37 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 5
TI Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors.

L7 ANSWER 38 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte -stimulating hormones.

L7 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanotropic peptide receptors: membrane markers of human melanoma cells

L7 ANSWER 40 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 6
TI Human epidermal melanocyte and keratinocyte melanocortin receptors: Visualization by melanotropic peptide conjugated microspheres (Latex beads).

L7 ANSWER 41 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 7
TI Melanocortin receptors: Identification and characterization by melanotropic peptide agonists and antagonists.

L7 ANSWER 42 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 8
TI Cyclic Lactam alpha-Melanotropin Analogues of Ac-Nle-4-cyclo(Asp-5,D-Phe-7,Lys-10) alpha-Melanocyte -Stimulating Hormone-(4-10)-NH-2 with Bulky Aromatic Amino Acids at Position 7 Show High Antagonist Potency and Selectivity at Specific Melanocortin Receptors.

L7 ANSWER 43 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 9
TI Design, synthesis, biology, and conformations of bicyclic alpha-melanotropin analogues.

L7 ANSWER 44 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 10
TI The melanotropic peptide, (Nle-4, D-Phe-7)alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation.

L7 ANSWER 45 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 11
TI Preformulation studies with melanotan-II: A potential skin cancer chemopreventive peptide.

L7 ANSWER 46 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 12
TI Multivalent melanotropic Peptide and Fluorescent Macromolecular Conjugates: New Reagents for Characterization of Melanotropin Receptors.

L7 ANSWER 47 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 13
TI Kinetics of degradation of a cyclic lactam analog of alpha-melanotropin (MT-II) in aqueous solution.

L7 ANSWER 48 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 14
TI Melanotropic peptides for therapeutic and cosmetic tanning of the skin.

L7 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanotropic peptides and melanoma cell receptors

L7 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI A new class of positively charged melanotropin analogs: a new concept in peptide design

L7 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Melanotropic peptides for the identification, localization (imaging) and chemotherapy of melanoma

L7 ANSWER 52 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 15
TI Design, synthesis, and conformation of superpotent and prolonged acting melanotropins.

L7 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Multivalent ligands for diagnosis and therapeutics

L7 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Design of different conformational isomers of the same peptide: α-melanotropin

L7 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antisense peptides of melanocyte-stimulating hormone (MSH): surprising results

=> d ibib abs l7 1-55

L7 ANSWER 1 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:589657 BIOSIS
DOCUMENT NUMBER: PREV200600593265
TITLE: Melanocortin metallopeptide constructs, combinatorial libraries and applications.
AUTHOR(S): Anonymous; Sharma, Shubh D. [Inventor]; Shi, Yiqun [Inventor]; Yang, Wei [Inventor]; Cai, Hui-Zhi [Inventor]
CORPORATE SOURCE: Cranbury, NJ USA
ASSIGNEE: Palatin Technologies Inc
PATENT INFORMATION: US 07049398 20060523
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (MAY 23 2006)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Nov 2006
Last Updated on STN: 8 Nov 2006
AB Metallopeptides and metallopeptide combinatorial libraries specific for melanocortin receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and

peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.

L7 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:52833 CAPLUS
DOCUMENT NUMBER: 144:143091
TITLE: Cyclic peptide melanocortin-4 receptor antagonists for the treatment of cachexia and other disorders
INVENTOR(S): Sharma, Shubh D.; Rajpurohit, Ramesh; Shadiack, Annette M.; Shi, Yi-Qun; Burris, Kevin D.
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of 1;U.S. Ser. No. 638,071.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006014676	A1	20060119	US 2005-174845	20050705
WO 2003006620	A2	20030123	WO 2002-US22196	20020711
WO 2003006620	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004138136	A1	20040715	US 2003-638071	20030808
WO 2006014552	A2	20060209	WO 2005-US24125	20050706

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2001-304836P	P	20010711
WO 2002-US22196	A2	20020711
US 2003-638071	A2	20030808
US 2004-585971P	P	20040706
US 2000-606501	A2	20000628
US 2002-40547	A2	20020104

OTHER SOURCE(S): MARPAT 144:143091
GI



I

AB The invention discloses highly selective melanocortin-4 receptor antagonist cyclic hexapeptides I [R1 = H, NH2, etc.; R2 = C(O)NH, NHC(O), S, SS; R3 = 4-imidazolyl, 3-indolyl; R4a, R4b (when present) = OH, halo, etc.; R5 = NH2, NH(C=NH)NH2; R6 = (un)substituted 1- or 2-naphthyl, (un)substituted 3-indolyl; R7 = OH, N(R11)(R12); R11, R12 = H, C1-4 linear or branched alkyl (with proviso); x = 1-4; y = 1-5 (x + y = 2-7); z = 2-5], as well as a method for treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

L7 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:52895 CAPLUS
DOCUMENT NUMBER: 144:143092
TITLE: Cyclic peptide melanocortin-4 receptor antagonists for the treatment of cachexia and other disorders
INVENTOR(S): Sharma, Shubh D.; Rajpurohit, Ramesh; Shadiack, Annette M.; Shi, Yi-Qun; Burris, Kevin D.
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 638,071.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006014194	A1	20060119	US 2005-174851	20050705
WO 2003006620	A2	20030123	WO 2002-US22196	20020711
WO 2003006620	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004138136 A1 20040715 US 2003-638071 20030808
WO 2006014552 A2 20060209 WO 2005-US24125 20050706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
WO 2006014559 A2 20060209 WO 2005-US24138 20050706
WO 2006014559 A3 20061207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2001-304836P P 20010711
WO 2002-US22196 A2 20020711
US 2003-638071 A2 20030808
US 2004-585971P P 20040706
US 2000-606501 A2 20000628
US 2002-40547 A2 20020104
US 2005-174851 A 20050705
OTHER SOURCE(S): MARPAT 144:143092
GI



I

AB The invention discloses highly selective melanocortin-4 receptor antagonist cyclic hexapeptides I [R1 = H, NH2, R6C(O)NH; R2 = C(O)NH, NHC(O), S; R3a, R3b (when present) = OH, halo, alkyl, etc.; R4 = NH2, NH(C=NH)NH2; R5 = (un) substituted 1- or 2-naphthyl, (un) substituted 3-indolyl; R6 = H, NH2, etc.; x = 1-4; y = 1-5 (x + y = 2-7); z = 2-5], as well as a method for treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

L7 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:961972 CAPLUS
DOCUMENT NUMBER: 143:248665
TITLE: Preparation of bicyclic melanocortin -specific compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079574	A1	20050901	WO 2004-US1505	20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2004-US1505 20040121
OTHER SOURCE(S): MARPAT 143:248665
GI



I



Ser(Bzl)-D-Phe(4-Cl)

II

AB The invention discloses melanocortin receptor (MC-R)-specific bicyclic compds. having the structure I [R1 is L1-J, where L1 is a linker and J is a ring structure; R2 is (CH2)1-6-W, where W is a heteroarom. unit with at least one cationic center, hydrogen bond donor or acceptor in which at least one atom is N; R3 is L2-Q, where L2 is a linker and Q is (un)substituted Ph or naphthyl: X = CH2 or CO; X1 is null or CH2], or stereoisomers or pharmaceutically-acceptable salts, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors and have utility in the treatment of melanocortin receptor-related disorders and conditions. Thus, pyrroloimidazolyl peptide II was prepared and assayed for competitive binding against 128I-NDP-α-MSH (90, 14, 81 and 86% inhibition for MC1-R, MC3-R, MC4-R and MC5-R, resp., at 1 μM).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1333961 CAPLUS
DOCUMENT NUMBER: 144:64389
TITLE: α-MSH-, γ-MSH-, and bombesin-derived metallopeptide compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Rajpurohit, Ramesh; Cai, Hui-Zhi; Bastos, Margarita
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 769,695.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005282739	A1	20051222	US 2005-188552	20050725
WO 2002064734	A2	20020822	WO 2001-US50075	20011219
WO 2002064734	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005014193	A1	20050120	US 2003-464117	20030617
US 2004248212	A1	20041209	US 2004-769695	20040130

PRIORITY APPLN. INFO.:

US 2000-256842P	P	20001219
US 2001-304835P	P	20010711
US 2001-327835P	P	20011004
WO 2001-US50075	A2	20011219
US 2003-444129P	P	20030131
US 2003-464117	A2	20030617
US 2004-769695	A2	20040130
US 2004-590933P	P	20040723

AB The invention discloses metallopeptides with a sequence of a biol. active α-MSH, γ-MSH, or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the

three position to the n position, with a metal ion complexed thereto, with any proline residue which is either of the two residues on the immediately adjacent amino-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog. In one embodiment, the metal atom is rhenium.

L7 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1078201 CAPLUS
DOCUMENT NUMBER: 143:319194
TITLE: Phosphodiesterase V inhibitor combination with melanocortin 3 and/or 4 receptor agonist for treatment of sexual dysfunction
INVENTOR(S): Diamond, Lisa E.; Earle, Dennis; Shadiack, Annette M.; Sharma, Shubh D.; Spana, Carl
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 638,071.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005222014	A1	20051006	US 2005-139730	20050526
US 6579968	B1	20030617	US 2000-606501	20000628
EP 1593384	A2	20051109	EP 2005-75914	20000629
EP 1593384	A3	20060426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002107182	A1	20020808	US 2002-40547	20020104
US 6794489	B2	20040921		
US 2004138136	A1	20040715	US 2003-638071	20030808
WO 2005117935	A1	20051215	WO 2005-US18739	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 1999-142346P	P 19990629
US 2000-194987P	P 20000405
US 2000-606501	A2 20000628
US 2002-40547	A2 20020104
US 2003-638071	A2 20030808
US 2004-575082P	P 20040527
EP 2000-950283	A3 20000629
WO 2002-US22196	A 20020711
US 2005-139730	A 20050526

AB The invention discloses a multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration of a type V phosphodiesterase (PDE-5) inhibitor, e.g. sildenafil, preferably where the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, e.g. Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141), preferably wherein

the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.

L7 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:735324 CAPLUS
DOCUMENT NUMBER: 143:211935
TITLE: Substituted melanocortin receptor-specific piperazine compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun; Rajpurohit, Ramesh; Wu, Zhijun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 837,519.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005176728	A1	20050811	US 2005-99814	20050405
WO 2003013571	A1	20030220	WO 2002-US25574	20020812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004157264	A1	20040812	US 2004-762079	20040121
WO 2005102340	A1	20051103	WO 2004-US1462	20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004224957	A1	20041111	US 2004-837519	20040430

PRIORITY APPLN. INFO.:	US 2001-311404P	P	20010810
	WO 2002-US25574	A2	20020812
	US 2003-467442P	P	20030501
	US 2003-474497P	P	20030530
	US 2004-762079	A2	20040121
	US 2004-546393P	P	20040219
	US 2004-559741P	P	20040405
	US 2004-563739P	P	20040419
	US 2004-837519	A2	20040430

OTHER SOURCE(S): MARPAT 143:211935
GI



I



II

AB Melanocortin receptor-specific compds. of the general formulas I and II and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure; L is a linker; W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor; Q includes a substituted or unsubstituted aromatic carbocyclic ring; R6 = H, :O, :S or CH3; R7 = NH2, NH-R8, or R8-N-R8; R8 = C1 to C6 linear or branched chain or an amine capping group, and where there are two R8 groups, each R8 is independently a C1 to C6 linear or branched chain or an amine capping group; y = 0-6; and z =0-6, and the carbon atom marked with an asterisk can have any stereochem. configuration, and optionally with one or two addnl. ring substituents, which compds. bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compds. of the invention.

L7 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:672855 CAPLUS
DOCUMENT NUMBER: 143:166711
TITLE: Metallopeptide compositions for treatment of sexual dysfunction
INVENTOR(S): Sharma, Shubh; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 640,755.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005164914	A1	20050728	US 2005-36273	20050114
US 5891418	A	19990406	US 1995-476652	19950607
US 6027711	A	20000222	US 1996-660697	19960605
WO 2002064091	A2	20020822	WO 2002-US4431	20020213
WO 2002064091	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004038897	A1	20040226	US 2003-640755	20030813
PRIORITY APPLN. INFO.:			US 1995-476652	A2 19950607
			US 1996-660697	A3 19960605
			US 2000-483837	A2 20000117
			US 2001-268591P	P 20010213
			WO 2002-US4431	A1 20020213
			US 2003-640755	A2 20030813
			US 2004-536691P	P 20040114

OTHER SOURCE(S): MARPAT 143:166711

AB Metallopeptide compns. are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid side chain moieties, and are further characterized in that the metallopeptides preferably do not bind or significantly bind to a melanocortin receptor. Preparation of the metallopeptides is described.

L7 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:527392 CAPLUS
DOCUMENT NUMBER: 143:20084
TITLE: Naphthalene-containing melanocortin receptor-specific small molecule
INVENTOR(S): Sharma, Shubh D.; Shadiack, Annette M.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh; Burris, Kevin; Purma, Papireddy
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 837,519.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005130988	A1	20050616	US 2005-36282	20050114
WO 2003013571	A1	20030220	WO 2002-US25574	20020812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004152134	A1	20040805	US 2004-761889	20040121
US 2004157264	A1	20040812	US 2004-762079	20040121
WO 2005102340	A1	20051103	WO 2004-US1462	20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004224957	A1	20041111	US 2004-837519	20040430

PRIORITY APPLN. INFO.:

US 2001-311404P	P	20010810
WO 2002-US25574	A2	20020812
US 2003-467442P	P	20030501
US 2003-474497P	P	20030530
US 2004-536606P	P	20040114
US 2004-761889	A2	20040121
US 2004-762079	A2	20040121
US 2004-546393P	P	20040219
US 2004-559741P	P	20040405
US 2004-563739P	P	20040419
US 2004-837519	A2	20040430

OTHER SOURCE(S): MARPAT 143:20084

AB A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula I (where R1 = a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, L = a conformationally restricted ring system consisting of a single ring or bicyclic nonarom. carbocyclic ring system, etc., R2= -(CH2)4NH2,-(CH2)3NHC(NH2)=NH, etc., R3 = L-or D-isomer of Phe, Phe(4-F), Phe(4-Br), etc., and Rx = H, C-C6 aliphatic linear chain, etc.).

L7 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:497489 CAPLUS

DOCUMENT NUMBER: 143:26632

TITLE: Preparation of thieno[2,3-d]pyrimidine-2,4-diones as melanocortin receptor modulators

INVENTOR(S): Sharma, Shubh D.; Shi, Yiqun

PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 837,519.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005124636	A1	20050609	US 2005-40838	20050121
WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004152134	A1	20040805	US 2004-761889	20040121
US 2004157264	A1	20040812	US 2004-762079	20040121
WO 2005102340	A1	20051103	WO 2004-US1462	20040121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004224957	A1	20041111	US 2004-837519		20040430
PRIORITY APPLN. INFO.:			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-467442P	P	20030501
			US 2003-474497P	P	20030530
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-837519	A2	20040430

OTHER SOURCE(S): MARPAT 143:26632

GI



I



II



III

AB Title compds. I [R1 = L1-J; R2 = L2-W; R3 = L3-T; R4 = L4-Q; L1 = bond or linker with provisos; J = carbocyclic ring group comprising at least one aromatic ring; L2 = (CX)m; W = (un)substituted aromatic carbocyclic ring, non-aromatic carbocyclic ring, aromatic fused carbocyclic rings, etc.; L3, L4 = (CH2)m; T = heteroatom unit with at least one cationic center with provisos; Q = carbocyclic ring comprising at least one aromatic ring; X = H, H2, alkyl; m = 1-6] and their pharmaceutically acceptable salts were prepared For example, 4-chlorobenzyl chloride N-alkylation of pyrimidine II, afforded thienopyrimidinyldione III (no data). Compds. I are claimed to be useful for the treatment of melanocortin receptor-associated disorders.

L7 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2005:59906 CAPLUS
DOCUMENT NUMBER:	142:148744
TITLE:	Identification of target-specific folding sites in proteins using metallopeptide derivatives of sequences of interest
INVENTOR(S):	Sharma, Shubh D.; Shi, Yi-qun
PATENT ASSIGNEE(S):	USA

SOURCE: U.S. Pat. Appl. Publ., 75 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005014193	A1	20050120	US 2003-464117		20030617
US 2004248212	A1	20041209	US 2004-769695		20040130
US 2005282739	A1	20051222	US 2005-188552		20050725
PRIORITY APPLN. INFO.:			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	A1	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617
			US 2004-769695	A2	20040130
			US 2004-590933P	P	20040723

AB A method of identifying peptides that take up folded conformations and that bind to specific protein target is described. The method involves creating a systematic series of substitution derivs. of the peptide. These derivs. use amino acids or amino acid analogs containing a nitrogen or sulfur atom that can bind to a metal atom. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The structure of the metallopeptide can then be determined and a novel pharmacophore can be identified. The invention provides for defined pharmacophores of receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

L7 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:425889 CAPLUS
DOCUMENT NUMBER: 144:481641
TITLE: Melanocortin metallopeptide constructs, combinatorial libraries, and therapeutic applications
INVENTOR(S): Cai, Hui-Zhi; Yang, Wei; Shi, Yi-Qun; Sharma, Shubh D.
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: Aust. Pat. Appl., 81 pp.
CODEN: AUXXCM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
AU 2005201166	A1	20050505	AU 2005-201166		20050317
PRIORITY APPLN. INFO.:			AU 2000-58742	A3	20000615

AB The present invention relates to metallopeptides, metal ion-complexed peptidomimetics, and metallo-constructs, including metallopeptide combinatorial libraries, metal ion-complexed peptidomimetic and peptide-like combinatorial libraries and metallo-construct combinatorial libraries, specific for melanocortin receptors, including methods for the use and making of the same. The invention also relates to methods for synthesizing and assembling such libraries, and methods for identification and characterization of library constituents which are capable of binding a melanocortin receptor of interest, or

mediating a melanocortin receptor-related biol. activity of interest. Metallopeptides of this invention that are melanocortin receptor 1 specific can be used as radiodiagnostic agents or radiotherapeutic agents when complexed to radionuclides. Metallopeptides of this invention that are melanocortin receptor 1 specific can be used as chemopreventive agents against sun-induced neoplastic activity in human skin. Metallopeptides of this invention that are melanocortin receptor 4 antagonists can also be used as a therapeutic agent in eating disorders.

L7 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740117 CAPLUS
DOCUMENT NUMBER: 141:256945
TITLE: Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Rajpurohit, Ramesh; Bastos, Margarita; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075830	A2	20040910	WO 2004-US2933	20040202
WO 2004075830	A3	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2004248212	A1	20041209	US 2004-769695	20040130
CA 2516750	A1	20040910	CA 2004-2516750	20040202
EP 1594442	A2	20051116	EP 2004-737267	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2003-444129P	P	20030131
US 2004-769695	A	20040130
US 2000-256842P	P	20001219
US 2001-304835P	P	20010711
US 2001-327835P	P	20011004
WO 2001-US50075	A1	20011219
US 2003-464117	A2	20030617
WO 2004-US2933	W	20040202

AB The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. A residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of the peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide with a conformationally fixed and predictable secondary

structure of the residues involved in metal ion complexation. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality. The method is exemplified by α-MSH and bombesin analogs containing L-/D-cysteine insertions or substitutions complexed to the rhenium metal ion, and their binding to their resp. receptors.

L7 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41502 CAPLUS
DOCUMENT NUMBER: 140:105305
TITLE: Peptide composition for treatment of sexual dysfunction
INVENTOR(S): Sharma, Shubh D.; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004005324	A2	20040115	WO 2003-US21417		20030709
WO 2004005324	A3	20040325			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003248888	A1	20040123	AU 2003-248888		20030709
BR 2003005628	A	20040908	BR 2003-5628		20030709
US 2005124553	A1	20050609	US 2005-31898		20050107
PRIORITY APPLN. INFO.:			US 2002-394756P	P	20020709
			WO 2003-US21417	W	20030709

OTHER SOURCE(S): MARPAT 140:105305
AB Peptides for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and one or more second sexual dysfunction pharmaceutical agents are disclosed.

L7 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965987 CAPLUS
DOCUMENT NUMBER: 141:411221
TITLE: Preparation of piperazine melanocortin receptor-specific compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun; Rajpurohit, Ramesh; Wu, Zhijun; Purma, Papireddy; Shadiack, Annette M.; Burris, Kevin D.
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 69 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004224957	A1	20041111	US 2004-837519		20040430
AU 2004235792	A1	20041118	AU 2004-235792		20040503
WO 2004098602	A1	20041118	WO 2004-US13803		20040503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1622618	A1	20060208	EP 2004-751262		20040503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004010694	A	20060620	BR 2004-10694		20040503
CN 1816337	A	20060809	CN 2004-80018907		20040503
JP 2006525369	T	20061109	JP 2006-514263		20040503
US 2005130988	A1	20050616	US 2005-36282		20050114
US 2005124636	A1	20050609	US 2005-40838		20050121
US 2005176728	A1	20050811	US 2005-99814		20050405
US 2006287330	A1	20061221	US 2006-464051		20060811
US 2006287331	A1	20061221	US 2006-464053		20060811
US 2006287332	A1	20061221	US 2006-464069		20060811
PRIORITY APPLN. INFO.:			US 2003-467442P	P	20030501
			US 2004-546393P	P	20040219
			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
			US 2004-536606P	P	20040114
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A	20040430
			WO 2004-US13803	W	20040503
			US 2005-707488P	P	20050811
OTHER SOURCE(S):	MARPAT 141:411221				

GI



I



II

AB The invention relates to amino acid-derived piperazine compds. I [X is CH2, CO or CS; R1 is -L1-J; one of R2a and R2b is -L2-W and the other is H; R3 is -L3-Q; L1 is a bond or a linker unit comprising from one to eight backbone atoms selected from carbon, sulfur, oxygen or nitrogen; J is a ring structure, e.g., an (un)substituted aromatic or non-aromatic carbocyclic ring; L2 is a bond or (CH2)1-6; W is a heteroatom unit with at least one cationic center, hydrogen bond donor or acceptor (at least one heteroatom is nitrogen or oxygen); L3 is a bond or a linker unit comprising from one to nine backbone atoms selected from carbon, sulfur, oxygen or nitrogen; Q is (un)substituted Ph or naphthyl; one or two of R4a, R4b, R5a and R5b are independently -L2-W or an aliphatic chain and the others are H, provided that at least one of R4a and R4b and at least one of R5a and R5b is H], including enantiomers, stereoisomers, diastereoisomers or pharmaceutically-acceptable salts, which bind with high affinity to one or more melanocortin receptors (MCR) and may be employed for treatment of melanocortin receptor-associated conditions or disorders. Thus, piperazine derivative II was prepared via reactions of 2-naphthylacetic acid, (R)-(-)-2-amino-1-propanol, Fmoc-L-Arg(Boc)2-OH (Fmoc = fluorenylmethoxycarbonyl, Boc = tert-butoxycarbonyl), and Boc-D-4-chloro-2-methyl-L-phenylalanine. Compound II was shown to be a partial agonist as to MC4-R and in rats caused a decrease in food intake (administration 2 h prior to food presentation) and induced penile erection at 0.3-30 μg/Kg.

L7 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703130 CAPLUS
DOCUMENT NUMBER: 141:207526
TITLE: Preparation of pyrrolidine melanocortin -specific compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun; Wu, Zhijun; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of Appl. No PCT/US02/25574.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167201	A1	20040826	US 2004-776657	20040210
WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-311404P P 20010810
WO 2002-US25574 A2 20020812

OTHER SOURCE(S): MARPAT 141:207526
GI



I II

AB The invention relates to melanocortin receptor (MC-R)-specific pyrrolidine compds. I [R1 is -L1-J, where L1 is a linker (CH2)0-6, O, NH, etc. and J is a ring structure; R2 is CO-W or CONH(CH2)0-6-W, where W is a heteroatom unit with at least one nitrogen atom and at least one cationic center, hydrogen bond donor or acceptor; R3 is -L2-Q, where L2 is a linker COCH(NH2)CH2, COCH2O, 5-carbonyl-substituted 3-pyrrolidinyl, etc.; preferably R3 is a D-amino acid with at least one (un)substituted Ph or naphthyl ring or 1-3 addnl. amino acid residues, optionally with an amine capping group] and their pharmaceutically-acceptable salts, which are agonists/antagonists at one or more melanocortin receptors and having utility in the treatment of melanocortin receptor-related disorders and conditions. Thus, peptide II was prepared by the solid-phase method and shown to be an agonist of MC1-R (Ki = 10 nM).

L7 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:652533 CAPLUS
DOCUMENT NUMBER: 141:191073
TITLE: Preparation of piperazines as melanocortin -specific agonists, antagonists, or mixed agonists and antagonists.
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun; Wu, Zhijun; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 70 pp., Cont.-in-part of Appl. No. PCT/US02/25574.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004157264	A1	20040812	US 2004-762079		20040121
WO 2003013571	A1	20030220	WO 2002-US25574		20020812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2005102340	A1	20051103	WO 2004-US1462		20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005130988	A1	20050616	US 2005-36282		20050114
US 2005124636	A1	20050609	US 2005-40838		20050121
US 2005176728	A1	20050811	US 2005-99814		20050405
PRIORITY APPLN. INFO.:			US 2001-311404P	P	20010810
			WO 2002-US25574	A2	20020812
			US 2003-474497P	P	20030530
			US 2003-467442P	P	20030501
			US 2004-536606P	P	20040114
			US 2004-538100P	P	20040121
			US 2004-761889	A2	20040121
			US 2004-762079	A2	20040121
			US 2004-546393P	P	20040219
			US 2004-559741P	P	20040405
			US 2004-563739P	P	20040419
			US 2004-837519	A2	20040430
OTHER SOURCE(S):	MARPAT 141:191073				
GI					



I











II

AB Title compds. [I; R1 = L1J, H; R2 = (CH2)yW, J, L1J; R3 = L2Q; L1 = (CH2)y, O(CH2)y, NH(CH2)y, CO(CH2)y, CO2(CH2)y, CH2CONH; J = (substituted) aryl, carbocyclyl, carbobicyclyl, heterobicyclyl; W = heteroatom unit with ≥1 cationic center, hydrogen bond donor, or hydrogen bond acceptor wherein ≥1 atom = N; L2 = Q1, Q2, Q3, Q4, etc.; Q = (substituted) Ph, naphthyl; R4 = H, R5, R5R6; R5 = amino acid residue, amine capping group; R6 = H, amine capping group; y = 1-6], were prepared Thus, title compound (II; Q5 = 2,4-dichloro-D-phenylalanyl) (general preparation given) at 1
μM gave 95% inhibition of melanocortin MC4-R.

L7 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633168 CAPLUS
DOCUMENT NUMBER: 141:151030
TITLE: Bicyclic melanocortin-specific compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Wu, Zhijun; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of WO 2003 13,571.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152134	A1	20040805	US 2004-761889	20040121
WO 2003013571	A1	20030220	WO 2002-US25574	20020812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005130988	A1	20050616	US 2005-36282	20050114
US 2005124636	A1	20050609	US 2005-40838	20050121
PRIORITY APPLN. INFO.:			US 2001-311404P	P 20010810
			WO 2002-US25574	A2 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-536606P	P 20040114
			US 2004-538100P	P 20040121
			US 2004-761889	A2 20040121
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219
			US 2004-559741P	P 20040405
			US 2004-563739P	P 20040419
			US 2004-837519	A2 20040430

OTHER SOURCE(S): MARPAT 141:151030

GI



I

AB The invention discloses melanocortin receptor-specific bicyclic compds. having the structure I (R1 = L1-J wherein L1 is a linker and J is a ring structure selected form the group consisting of substituted or unsubstituted aromatic carboxylic rings, substituted or unsubstituted non-aromatic carboxylic rings, substituted or unsubstituted aromatic fused carbobicyclic ring groups, etc.; R2 = (CH2)y-W wherein W is a heteroarom. unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor wherein at least one atom is N; R3 = L2-Q wherein L2 is a linker and Q is an aromatic carboxylic ring selected from the group consisting of Ph, substituted Ph, naphthyl and substituted naphthyl: X = CH2 or C=O and z is 0 or 1), and stereoisomer and pharmaceutically acceptable salts thereof, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Pharmaceutical compns. containing a compound of structure I and methods relating to the use thereof for treating eating disorders and sexual dysfunction are also disclosed.

L7 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2004:569853 CAPLUS
DOCUMENT NUMBER:	141:117192
TITLE:	Cyclic peptide compositions and methods for treatment of sexual dysfunction
INVENTOR(S):	Sharma, Shubh D.; Shadiack, Annette M.; Rajpurohit, Ramesh; Yang, Wei
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 40,547. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	7
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004138136	A1	20040715	US 2003-638071	20030808

US 6579968	B1	20030617	US 2000-606501		20000628
EP 1593384	A2	20051109	EP 2005-75914		20000629
EP 1593384	A3	20060426			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY					
US 2002107182	A1	20020808	US 2002-40547		20020104
US 6794489	B2	20040921			
WO 2003006620	A2	20030123	WO 2002-US22196		20020711
WO 2003006620	A3	20031127			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2005014617	A2	20050217	WO 2004-US25749		20040809
WO 2005014617	A3	20050707			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1667700	A2	20060614	EP 2004-780562		20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
US 2005222014	A1	20051006	US 2005-139730		20050526
US 2006014676	A1	20060119	US 2005-174845		20050705
US 2006014194	A1	20060119	US 2005-174851		20050705
US 2006111281	A1	20060525	US 2005-269271		20051109
PRIORITY APPLN. INFO.:			US 2000-606501	A2	20000628
			US 2002-40547	A2	20020104
			WO 2002-US22196	A	20020711
			US 1999-142346P	P	19990629
			US 2000-194987P	P	20000405
			EP 2000-950283	A3	20000629
			US 2001-304836P	P	20010711
			US 2003-638071	A	20030808
			US 2004-575082P	P	20040527
			US 2004-585971P	P	20040706
			WO 2004-US25749	W	20040809

OTHER SOURCE(S): MARPAT 141:117192

GI



I

AB The invention provides cyclic peptides I [R1 = H, N(R6)(R7); R2, R3, R5 = H, C1-6 (un)branched alkyl, aromatic amino acid side chain moiety, with provisos; R4 = C1-6 (un)branched chain amino acid side chain, neutral H-bonding or pos. charged amino acid side chain moiety; R6 = H, C1-4 (un)branched alkyl, C1-4 aralkyl; C1-4 ω-amino derivative; R7 = H, (un)branched C1-7 alkyl, etc.; m = 1-4; p = 1-5 (m + p = 2-7)]. Further provided are compns. and methods for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminal hydroxyl group. Methods of administration include injection, oral, urethral, vaginal, nasal and mucosal administration. The peptides of the invention are functional melanocortin agonists.

L7 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:133079 CAPLUS
DOCUMENT NUMBER: 138:188071
TITLE: Peptidomimetics of biologically active metallopeptides
INVENTOR(S): Sharma, Shubh D.; Shi, Yiqun; Rajpurohit, Ramesh; Wu, Zhijun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013571	A1	20030220	WO 2002-US25574	20020812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462200	A1	20030220	CA 2002-2462200	20020812
EP 1425029	A1	20040609	EP 2002-768507	20020812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504043	T	20050210	JP 2003-518577	20020812
US 2004152134	A1	20040805	US 2004-761889	20040121
US 2004157264	A1	20040812	US 2004-762079	20040121
US 2004167201	A1	20040826	US 2004-776657	20040210
US 2004171520	A1	20040902	US 2004-776419	20040210
US 2005130988	A1	20050616	US 2005-36282	20050114

US 2005124636	A1	20050609	US 2005-40838	20050121
US 2005176728	A1	20050811	US 2005-99814	20050405
PRIORITY APPLN. INFO.:			US 2001-311404P	P 20010810
			WO 2002-US25574	W 20020812
			US 2003-467442P	P 20030501
			US 2003-474497P	P 20030530
			US 2004-536606P	P 20040114
			US 2004-538100P	P 20040121
			US 2004-761889	A2 20040121
			US 2004-762079	A2 20040121
			US 2004-546393P	P 20040219
			US 2004-559741P	P 20040405
			US 2004-563739P	P 20040419
			US 2004-837519	A2 20040430

OTHER SOURCE(S): MARPAT 138:188071
GI



I

AB The invention relates to a method of deriving a peptidomimetic of a biol. active metallopeptide. The peptidomimetic contains at least one non-peptide ring structure and at least two amino acid-related elements. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5 and 6-5 bicyclic fused ring structure melanocortin receptor-specific peptidomimetics. The examples describe the synthesis of pyrrolidines, 2-piperazinones [e.g., I [R = BuCH2CH2CO-Ser(Bzl)-D-Phe(2-Cl)]], hexahydropyrrolo[1,2-a]pyrazin-4-ones, hexahydropyrrolo[1,2-a]imidazol-3-ones, 1,4-benzodiazepines, and piperazines. Competitive inhibition testing of compound I against α-MSH yielded the following results at 1 μM: melanocortin-1 receptor (MC1-R) 96%, MC3-R 51%, MC4-R 99%, and MC5-R 82%.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:58220 CAPLUS
DOCUMENT NUMBER: 138:117676
TITLE: Linear and cyclic melanocortin receptor-specific peptides, and therapeutic use
INVENTOR(S): Sharma, Shubh D.; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003006620	A2	20030123	WO 2002-US22196		20020711
WO 2003006620	A3	20031127			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2453515	A1	20030123	CA 2002-2453515		20020711
AU 2002322466	A2	20030129	AU 2002-322466		20020711
EP 1441750	A2	20040804	EP 2002-756458		20020711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2004534851	T	20041118	JP 2003-512379		20020711
US 2004138136	A1	20040715	US 2003-638071		20030808
US 2005038230	A1	20050217	US 2004-756212		20040112
US 2006014676	A1	20060119	US 2005-174845		20050705
US 2006014194	A1	20060119	US 2005-174851		20050705
US 2006111281	A1	20060525	US 2005-269271		20051109
PRIORITY APPLN. INFO.:			US 2001-304836P	P	20010711
			US 1999-142346P	P	19990629
			US 2000-194987P	P	20000405
			US 2000-606501	A2	20000628
			US 2002-40547	A2	20020104
			WO 2002-US22196	W	20020711
			US 2003-638071	A2	20030808
			US 2004-585971P	P	20040706

OTHER SOURCE(S): MARPAT 138:117676

AB Linear and cyclic peptides are provided which are specific to melanocortin receptors and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. The peptides of the invention may be used to treat e.g. erectile dysfunction and eating disorders.

L7 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:634923 CAPLUS

TITLE: Melanocortin-4 receptor selective small molecules

AUTHOR(S): Wu, Zhijun; Rajpurohit, Ramesh; Shi, Yiqun; Sharma, Shubh

CORPORATE SOURCE: Department of Chemistry, Palatin Technologies, Inc, Cranbury, NJ, 08512, USA

SOURCE: Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), MEDI-315. American Chemical Society: Washington, D. C.
CODEN: 69EKY9

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB The melanocortin-4 receptor is a drug target for developing therapeutics for various feeding disorders including obesity and cachexia. Various alpha-melanotropin (the endogenous 13 amino acid peptide) based ligands have been shown to modulate feeding behavior of rats under exptl. conditions. We have developed a series of tri-substituted oxopiperazine ring compds. [Fig. 1] as MC-4R selective small mol. agents. One of these agents, (2S)-1-(4-Cl-D-Phe)-2-(3-gaunidino-propyl)-3-oxo-4-naphthaleneethyl-piperazine, is an agonist with a Ki of 79 nM. SAR studies of affinity and receptor selectivity with a series of compds. with different R groups at the 4-position of the oxopiperazine ring will be presented.

L7 ANSWER 23 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:558167 BIOSIS
DOCUMENT NUMBER: PREV200300559042
TITLE: Melanocortin-4 receptor selective small molecules.
AUTHOR(S): Wu, Zhijun [Reprint Author]; Rajpurohit, Ramesh [Reprint Author]; Shi, Yiqun [Reprint Author]; Sharma, Shubh [Reprint Author]
CORPORATE SOURCE: Department of Chemistry, Palatin Technologies, Inc, 4C Cedar Brook Drive, Cranbury, NJ, 08512, USA zwu@palatin.com
SOURCE: Abstracts of Papers American Chemical Society, (2003) Vol. 226, No. 1-2, pp. MEDI 315. print.
Meeting Info.: 226th ACS (American Chemical Society) National Meeting. New York, NY, USA. September 07-11, 2003. American Chemical Society.
ISSN: 0065-7727 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003

L7 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:637788 CAPLUS
DOCUMENT NUMBER: 137:179841
TITLE: Identification of target-specific folding sites in peptides and proteins
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002064734	A2	20020822	WO 2001-US50075		20011219
WO 2002064734	A3	20031120			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2436789	A1	20020822	CA 2001-2436789		20011219
EP 1379283	A2	20040114	EP 2001-994412		20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005501220	T	20050113	JP 2002-565049		20011219
US 2004248212	A1	20041209	US 2004-769695		20040130
US 2005282739	A1	20051222	US 2005-188552		20050725
PRIORITY APPLN. INFO.:			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004

WO 2001-US50075	W	20011219
US 2003-444129P	P	20030131
US 2003-464117	A2	20030617
US 2004-769695	A2	20040130
US 2004-590933P	P	20040723

AB The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a min. of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The invention further provides methods to determine the specific sequence and local three-dimensional structure of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biol. activity of interest and methods to determine the pharmacophore of receptors or targets of interest. The invention provides for defined pharmacophores or receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

L7 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:637480 CAPLUS
DOCUMENT NUMBER:	137:190724
TITLE:	Melanocortin metallopeptides for treatment of sexual dysfunction
INVENTOR(S):	Sharma, Shubh D.; Shi, Yi-qun; Yang, Wei; Cai, Hui-zhi; Shadiack, Annette
PATENT ASSIGNEE(S):	Palatin Technologies, Inc., USA
SOURCE:	PCT Int. Appl., 58 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064091	A2	20020822	WO 2002-US4431	20020213
WO 2002064091	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004038897	A1	20040226	US 2003-640755	20030813
US 2005164914	A1	20050728	US 2005-36273	20050114

PRIORITY APPLN. INFO.:	US 2001-268591P	P	20010213
	US 1995-476652	A2	19950607
	US 1996-660697	A3	19960605

US 2000-483837	A2	20000117
WO 2002-US4431	A	20020213
US 2003-640755	A2	20030813
US 2004-536691P	P	20040114

OTHER SOURCE(S): MARPAT 137:190724

AB Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.

L7 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:618187 CAPLUS

TITLE: Conformationally-restricted N-alkylated amino acid analogs of MT-II to probe the message sequence of α- melanotropin

AUTHOR(S): Yang, Wei Helen; Rajpurohit, Ramesh; Wang, Qing-Mei; Sharma, Shubh

CORPORATE SOURCE: Palatin Technologies, Inc, Edison, NJ, 08837, USA

SOURCE: Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002), MEDI-336. American Chemical Society: Washington, D. C.
CODEN: 69CZPZ

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Ac-Nle-Cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (MT-II), is a potent non-selective cyclic peptide analog of α- melanotropin in which the tetrapeptide message segment, His-D-Phe-Arg-Trp, is constrained with an Asp Lys lactam bridge. It is evident that this mol. is capable of presenting itself in different conformational states that facilitate its interaction with various melanocortin receptors (MC-1R, MC-3R, MC-4R, and MC-5R) with similar low nanomolar affinities. We have explored the effects of addnl. conformational restrictions within this tetrapeptide sequence towards causing a shift in receptor selectivity. This was accomplished by introducing various N-alkylated derivs. of these amino acids in MT-II, individually as well as in tandem to restrict the phi conformational space around an amino acid. The results showed that D-Phe position was most sensitive for this modification. N-Methylation of D-Phe totally abolished the affinity for all of the four receptors. However, N-Ethylation caused a shift towards MC-1R selectivity, although with somewhat lower potency. N-Methylation at Arg or Trp residue was well tolerated and resulted in analogs displaying appreciable preference towards binding of MC-1R and MC-4R. These results that have provided important information on SAR for the design of receptor specific peptidomimetics will be discussed.

L7 ANSWER 27 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:511102 BIOSIS

DOCUMENT NUMBER: PREV200200511102

TITLE: Conformationally restricted N-alkylated amino acid analogs of MT-II to probe the message sequence of alpha-melanotropin.

AUTHOR(S): Yang, Wei Helen [Reprint author]; Rajpurohit, Ramesh [Reprint author]; Wang, Qing-Mei [Reprint author]; Sharma, Shubh [Reprint author]

CORPORATE SOURCE: Palatin Technologies, Inc, 175 May Street, Suite 500, Edison, NJ, 08837, USA
wyang@palatin.com

SOURCE: Abstracts of Papers American Chemical Society, (2002) Vol.

224, No. 1-2, pp. MEDI 336. print.
Meeting Info.: 224th National Meeting of the American Chemical Society. Boston, MA, USA. August 18-22, 2002.
CODEN: ACSRAL. ISSN: 0065-7727.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Oct 2002
Last Updated on STN: 2 Oct 2002

L7 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:137478 CAPLUS
DOCUMENT NUMBER: 134:188233
TITLE: Melanocortin metallopeptide constructs, combinatorial libraries, and applications
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Yang, Wei; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013112	A1	20010222	WO 2000-US16396	20000615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379647	A1	20010222	CA 2000-2379647	20000615
EP 1208377	A1	20020529	EP 2000-944681	20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004519410	T	20040702	JP 2001-517163	20000615
US 7049398	B1	20060523	US 2002-49718	20020213
US 2006240481	A1	20061026	US 2006-419557	20060522
PRIORITY APPLN. INFO.:			US 1999-148994P	P 19990812
			WO 2000-US16396	W 20000615
			US 2002-49718	A3 20020213

OTHER SOURCE(S): MARPAT 134:188233
AB Metallopeptides and metallopeptide combinatorial libraries specific for melanocortin receptors are provided, for use in biol., pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:421334 CAPLUS
DOCUMENT NUMBER: 133:55661
TITLE: Metallopeptide combinatorial libraries synthesis and applications

INVENTOR(S): Sharma, Shubh D.; Shi, Yiqun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000036136	A1	20000622	WO 1999-US29743	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2353072	A1	20000622	CA 1999-2353072	19991214
EP 1141375	A1	20011010	EP 1999-964263	19991214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536295	T	20021029	JP 2000-588384	19991214
AU 760257	B2	20030508	AU 2000-20541	19991214
US 2002012948	A1	20020131	US 2001-883069	20010614
US 2006003386	A1	20060105	US 2005-221210	20050907

PRIORITY APPLN. INFO.:

US 1998-112235P	P	19981214
US 1995-476652	A	19950607
US 1996-660697	A	19960605
WO 1999-US29743	W	19991214
US 2001-883069	B3	20010614

AB Metallopeptide combinatorial libraries and methods of making libraries and metallopeptides are provided for use in biol., pharmaceutical and related applications. The combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at least one orthogonal sulfur-protecting group, in which the peptide, peptidomimetic or construct is conformationally fixed on deprotection of the sulfur and complexation of the metal ion-binding region with a metal ion. Methods of synthesis of these metallopeptides are described. Thereafter the library members may be screened to select those with the desired specificity and affinity.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:123168 CAPLUS
DOCUMENT NUMBER: 132:185495
TITLE: Structurally determined metallo-constructs peptides as imaging and diagnostic and radiotherapeutic agents
INVENTOR(S): Sharma, Shubh D.
PATENT ASSIGNEE(S): Rhomed Incorporated, USA
SOURCE: U.S., 61 pp., Cont.-in-part of U.S. 5,891,418.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6027711	A	20000222	US 1996-660697	19960605

US 5891418	A	19990406	US 1995-476652		19950607
CA 2221146	A1	19961219	CA 1996-2221146		19960606
WO 9640293	A1	19961219	WO 1996-US9840		19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA					
AU 9663300	A	19961230	AU 1996-63300		19960606
AU 719556	B2	20000511			
EP 831939	A1	19980401	EP 1996-922423		19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
BR 9609400	A	19991214	BR 1996-9400		19960606
JP 2001518055	T	20011009	JP 1997-502043		19960606
IL 122392	A	20021110	IL 1996-122392		19960606
US 2003059422	A1	20030327	US 1999-387715		19990830
US 6551574	B2	20030422			
US 6331285	B1	20011218	US 1999-464358		19991215
US 2002012948	A1	20020131	US 2001-883069		20010614
US 2003165427	A1	20030904	US 2003-364842		20030211
US 7097824	B2	20060829			
US 2005164914	A1	20050728	US 2005-36273		20050114
US 2006040324	A1	20060223	US 2005-198510		20050805
PRIORITY APPLN. INFO.:			US 1995-476652	A2	19950607
			US 1996-660697	A	19960605
			WO 1996-US9840	W	19960606
			US 1998-78373P	P	19980318
			US 1998-112235P	P	19981214
			US 1999-387715	A3	19990830
			WO 1999-US29743	A	19991214
			US 2000-483837	A2	20000117
			US 2001-268591P	P	20010213
			WO 2002-US4431	A1	20020213
			US 2003-640755	A2	20030813
			US 2004-536691P	P	20040114

AB A metallo-construct, which may be a peptide, is provided for use as a biol., therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemical methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the type, R1XR2 (where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R1 and R2 each includes 0-20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R1 or R2 or both have a structure forming the balance of the conformationally constrained global secondary structure). All or a portion of the global secondary structure, which may be sychnol. or rhegnylogic, may form a ligand or mimic a known biol.-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion. D-Arg-Gly-D-Cys-β-Ala was prepared by standard methods and labeled with 99m Tc-sodium pertechnetate by using stannous salt as the reducing agent.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:192146 CAPLUS
DOCUMENT NUMBER: 128:257693
TITLE: Preparation of peptides having potent antagonist and agonist bioactivities at melanocortin

receptors
INVENTOR(S): Hadley, Mac E.; Hruby, Victor J.; Sharma, Shubh D.
PATENT ASSIGNEE(S): University of Arizona, Board of Regents, USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5731408	A	19980324	US 1995-420972	19950410
US 6054556	A	20000425	US 1997-980238	19971128
PRIORITY APPLN. INFO.:			US 1995-420972 A2	19950410

GI



Ac-Nle-Asp-His-X-Arg-Trp-Lys-NH_2 I

AB Cyclic lactam peptides I [X = D-3-(2-naphthyl)alanine (D-2-Nal), D-p-iodophenylalanine [D-(p-I)Phe]] provided potent and specific antagonists of the two neural melanocortin receptors and of the peripheral receptor. In particular, peptide I (X = D-2-Nal) was a potent antagonist of the MC3 and MC4 receptors with partial agonist activity, and a full agonist of the MC1 and MC5 receptors. Peptide I [X = D-(p-I)Phe] was a potent antagonist of the MC3 and MC4 receptors with partial agonist activity. Both peptides I have antagonist activities in the classical frog skin bioassay for pigmentation at the MC1 receptor.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 1
ACCESSION NUMBER: 1998:262508 BIOSIS
DOCUMENT NUMBER: PREV199800262508
TITLE: Prevention of reflex natriuresis after acute unilateral nephrectomy by melanocortin receptor antagonists.
AUTHOR(S): Ni, Xi-Ping; Kesterson, Robert A.; Sharma, Shubh D. ; Hruby, Victor J.; Cone, Roger D.; Wiedemann, Eckehart; Humphreys, Michael H. [Reprint author]
CORPORATE SOURCE: Box 1341, San Francisco General Hosp., Univ. California, San Francisco, CA 94143, USA
SOURCE: American Journal of Physiology, (April, 1998) Vol. 274, No. 4 PART 2, pp. R931-R938. print.
CODEN: AJPHAP. ISSN: 0002-9513.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Jun 1998
Last Updated on STN: 12 Aug 1998
AB gamma-Melanocyte-stimulating hormone (gamma-MSH), atrial natriuretic peptide (ANP), and oxytocin have been identified as candidate hormonal mediators of the reflex natriuresis that follows acute unilateral nephrectomy (AUN). Pharmacological characterization of the third melanocortin receptor (MC3-R) indicates that it uniquely responds to physiological concentrations of gamma-MSH. We tested the roles of gamma-MSH, ANP, and oxytocin in the postnephrectomy natriuresis by carrying out AUN during continuous intrarenal infusion of specific

antagonists for their cognate receptors. In anesthetized Sprague-Dawley rats, urinary sodium excretion (UNaV) increased from 0.34 +- 0.04 to 1.12 +- 0.11 mueq/min 90 min after AUN ($P < 0.001$). No change in UNaV occurred in rats undergoing a sham AUN procedure. Plasma immunoreactive gamma-MSH concentration was 53 +- 8 fmol/ml after sham AUN but 112 +- 17 fmol/ml after AUN ($P < 0.01$). SHU-9119 and SHU-9005 are substituted derivatives of alpha-MSH with potent antagonism at the MC3-R in vitro. Infusion of these compounds at 5 pmol/min completely blocked the natriuretic response to AUN despite a similar elevation in plasma gamma-MSH (111 +- 12 vs. 49 +- 8 fmol/ml in sham rats, $P < 0.01$). Intrarenal infusion of the ANP receptor antagonist A-71915 (5 pmol/min) or the oxytocin receptor antagonist (d(CH2)51, Tyr(Me)2,Orn8) vasotocin (10 pmol/min) effectively inhibited the natriuresis induced by intravenous infusion of ANP or oxytocin (each at 1 pmol/min), respectively, but did not block the natriuresis after AUN. Plasma immunoreactivity of these peptides was not increased after AUN. These results indicate that reflex natriuresis after AUN is accompanied by an increase in plasma gamma-MSH but not ANP or oxytocin concentration and is prevented by intrarenal infusion of receptor antagonists with selectivity for MC3-R. The data indicate that gamma-MSH or a closely related peptide mediates postnephrectomy natriuresis and provide further support for the possibility that gamma-MSH may play a wider role in sodium homeostasis.

L7 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:735794 CAPLUS
DOCUMENT NUMBER: 127:346663
TITLE: Preparation and biological activity of cyclic bridged α-MSH analogs
INVENTOR(S): Hadley, Mac E.; Hruby, Victor J.; Sharma, Shubh D.
PATENT ASSIGNEE(S): Competitive Technologies, Inc., USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 199,775, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5683981	A	19971104	US 1995-470343		19950606
US 5674839	A	19971007	US 1994-349902		19941206
US 5714576	A	19980203	US 1997-826676		19970407
PRIORITY APPLN. INFO.:			US 1987-53229	B2	19870522
			US 1988-212807	B1	19880629
			US 1990-611456	B2	19901113
			US 1992-938781	B1	19920831
			US 1994-199775	B2	19940222
			US 1992-916767	B1	19920717
			US 1994-349902	A3	19941206

GI



I



II



III

AB Novel cyclic bridged α-MSH analogs I and II (AA5, AA10, AA11 = L- or D-amino acid containing ω-amino or carboxyl group in the side chain; Xxx = 1-5 α-amino acid residues, each of which may be of L- or D-configuration, or linear or branched spacer chain containing terminal amino and/or carboxy groups; R1, R2 designates α-MSH1-13NH2, α-MSH1-12NH2, α-MSH1-11NH2, α-MSH4-13NH2, α-MSH4-10NH2) are described herein. With the described analogs, when administered in pharmaceutical compns., it is now possible to achieve normalization of hypopigmentation dysfunctions and to achieve darkening of the skin in the total absence of sun or UV light irradiation Thus, cyclic peptide III was prepared by standard solid-phase methods and displayed α-MSH relative potencies of 100 in a frog skin assay and 5 in a lizard skin assay.

L7 ANSWER 34 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 2

ACCESSION NUMBER: 1997:290902 BIOSIS
DOCUMENT NUMBER: PREV199799590105
TITLE: Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c(Asp-His-Phe-Arg-Trp-Ala-Lys)-NH-2, on human melanocortin receptors.
AUTHOR(S): Haskell-Luevano, Carrie; Nikiforovich, Gregory; Sharma, Shubh D.; Yang, Ying-Kui; Dickinson, Chris; Hruby, Victor J. [Reprint author]; Gantz, Ira
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ 85721, USA
SOURCE: Journal of Medicinal Chemistry, (1997) Vol. 40, No. 11, pp. 1738-1748.
CODEN: JMCMAR. ISSN: 0022-2623.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Jul 1997
Last Updated on STN: 9 Jul 1997

AB Examination of conformationally constrained melanotropin peptides (Ac-Nle-4-c(Asp-5-His-Phe-7-Arg-Trp-9-Ala-Lys)-NH-2) on four human melanotropin receptors (hMC1R, hMC3R, hMC4R, and hMC5R) resulted in identifying the importance of ligand stereochemistry at positions 5, 7, and 9 for agonist binding affinity and receptor selectivity. A trend in ligand structure-activity relationships emerged for these peptides, with the hMC1R and hMC4R possessing similar tendencies, as did the hMC3R and hMC5R. alpha-MSH (Ac-Ser-Tyr-Ser-Met-4-Glu-His-Phe-7-Arg-Trp-Gly-Lys-Pro-Val-NH-2), NDP-MSH (Ac-Ser-Tyr-Ser-Nle-4-Glu-HiS-D-Phe-7-Arg-Trp-Gly-Lys-Pro-Val-NH-2), and MTII (Ac-Nle-4-c(Asp-5,D-Phe-7-Lys-10)-alpha-MSH(4-10)-NH-2) were also examined at each of these melanocortin receptors. Interestingly, the linear NDP-MSH possessed greater binding affinity for the hMC3R and hMC5R than did the cyclic analogue MTII. The peptide Ac-Nle-c(Asp-His-Phe-Arg-D-

Trp-9-Ala-Lys)-NH-2 demonstrated the greatest differentiation in binding affinity between the hMC1R and hMC4R (78-fold). Analogue Ac-Nle-c(Asp-His-Phe-7-Arg-Trp-Ala-Lys)-NH-2 resulted in micromolar binding affinity (or greater) at the hMC3R and hMC5R, demonstrating the importance of D-Phe-7 for ligand binding potency at these receptors. Ac-c(Asp-His-Phe-Arg-Trp-Ala-Lys)-NH-2 resulted in loss of binding affinity at the hMC5R, implicating the importance of Nle-4 (or a hydrophobic residue in this position) for binding to this receptor. Ac-Nle-c(D-Asp-5-His-Phe-Arg-Trp-Ala-Lys)-NH-2 was unable to competitively displace (125I)NDP-MSH binding at micromolar concentrations on the hMC3R and hMC5R, suggesting the importance of chirality of Asp-5 either for ligand-receptor interactions or for orientation of the side chain lactam bridge and the structural integrity of the peptide conformation. Energy calculations performed for these peptides resulted in the identification of a low-energy ligand conformer family that is common to all the ligands. The differences in ligand binding affinities observed in this study are postulated to be a result of different ligand-receptor complexed interactions and not solely to the ligand structure.

L7 ANSWER 35 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 3

ACCESSION NUMBER: 1997:513441 BIOSIS
DOCUMENT NUMBER: PREV199799812644
TITLE: Selectivity of cyclic (D-Nal-7) and (D-Phe-7) substituted MSH analogues for the melanocortin receptor subtypes.
AUTHOR(S): Schioth, Helgi B. [Reprint author]; Muceniece, Ruta; Mutulis, Felikss; Prusis, Peteris; Lindeberg, Gunnar; Sharma, Shubh D.; Hruby, Victor J.; Wikberg, Jarl E. S. [Reprint author]
CORPORATE SOURCE: Dep. Pharmaceutical Pharmacol., Biomedical Cent., Box 591, 751 24 Uppsala, Sweden
SOURCE: Peptides (Tarrytown), (1997) Vol. 18, No. 7, pp. 1009-1013. CODEN: PPTDD5. ISSN: 0196-9781.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 1997
Last Updated on STN: 10 Dec 1997

AB The binding of the 2 cyclic lactam MSH (4-10) analogues (MTII, SHU9119), and 5 cyclic (Cys-4, Cys-10)alpha-MSH analogues were tested on cells transiently expressing the human MC1, MC3, MC4 and MC5 receptors. The results indicate a differential importance of the C-terminal (Lys-Pro-Val) and N-terminal (Ser-Tyr-Ser) of cyclic (Cys-4, Cys-10)alpha-MSH analogues in binding to the MC receptor subtypes. Substitution of D-Phe-7 by D-Nal(2')-7 in both the cyclic lactam MSH (4-10) and the cyclic disulphide MSH (4-10) analogues resulted in a shift in favour of selectivity for the MC4 receptor; the disulphide analogue, (Cys-4, D-Na)(2')-7 Cys-10)alpha-MSH (4-10) (HS9510), showing the highest selectivity for the MC4 receptor among all the substances tested. However, the cyclic lactams displayed an over all higher affinity for the MC receptors, than any of the cyclic disulphide MSH (4-10) analogues.

L7 ANSWER 36 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 4

ACCESSION NUMBER: 1997:178769 BIOSIS
DOCUMENT NUMBER: PREV199799470482
TITLE: Characterisation of D117A and H260A mutations in the melanocortin 1 receptor.
AUTHOR(S): Schioth, Helgi B. [Reprint author]; Muceniece, Ruta; Szardenings, Michael; Prusis, Peteris; Lindeberg, Gunnar; Sharma, Shubh D.; Hruby, Victor J.; Wikberg, Jarl E. S.
CORPORATE SOURCE: Dep. Pharmaceutical Pharmacol., Biomed. Center, Box 591,

751 24 Uppsala, Sweden
SOURCE: Molecular and Cellular Endocrinology, (1997) Vol. 126, No. 2, pp. 213-219.
CODEN: MCEND6. ISSN: 0303-7207.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Apr 1997
Last Updated on STN: 2 Jun 1997

AB Recent site directed mutagenesis studies on the melanocortin 1 (MC1) receptor have indicated the importance of D117 and H260 amino acid residues for the binding of alpha-MSH (melanocyte stimulating hormone). Here, we report the testing of 12 cyclic and linear MSH peptides on the D117A and H260A mutant receptors. Moreover, we constructed a double mutant which displayed a major loss in affinity for (Nle-4, D-Phe-7)alpha-MSH. Our new data of His-6 and Phe-7 substituted MSH peptides are compared with previous results and the hypothesis of putative interactions of D117 and H260 with single amino acids in the MSH peptide. Our conclusions are that the D117A and the H260A mutations may cause conformational changes in the receptor which can not be linked to any specific amino acid in the MSH-peptides.

L7 ANSWER 37 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 5
ACCESSION NUMBER: 1997:22523 BIOSIS
DOCUMENT NUMBER: PREV199799321726
TITLE: Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors.
AUTHOR(S): Sharma, Shubh D.; Jiang, Jinwen; Hadley, Mac E.; Bentley, David L.; Hruby, Victor J. [Reprint author]
CORPORATE SOURCE: Dep. Chemistry, Arizona Res. Laboratories, Univ. Arizona, Tucson, AZ 85721, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (1996) Vol. 93, No. 24, pp. 13715-13720.
CODEN: PNASA6. ISSN: 0027-8424.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jan 1997
Last Updated on STN: 23 Jan 1997

AB We developed two solid-phase reagent systems for microscopic visualization and characterization of melanocyte-stimulating hormone (MSH) receptors of melanoma cells. Multiple copies of (Nle-4,D-Phe-7)-alpha-MSH, a potent analog of alpha-MSH, were conjugated to microspheres (latex beads) or macrospheres (polyamide beads) through a thioether or disulfide bond. Binding between the beads and mouse and human melanoma cells was examined by scanning electron microscopy and by light microscopy. Each mouse and human melanoma cell (of all cell lines) evinced binding to the beads. Binding of the melanotropin conjugates was not restricted to any one phase of the cell cycle. Specificity of binding was demonstrated by several studies. Negative controls included cell types of nonmelanocyte origin (e.g., mammary cancer cells) and beads that lacked the melanotropic ligand or had other attached ligands. Beads with a disulfide-linked melanotropin analog served as a direct control. Treatment of these beads with DTT during or before incubation of the beads with melanoma cells (resulting in-release of the MSH analog from the beads) eliminated binding of the beads to melanoma cells. Binding interactions between melanoma cells and melanotropin-bound beads also could be abolished by prior incubation with unconjugated MSH analog. During these experiments, certain membrane receptor-hormone associated phenomena, such as capping (aggregation) of the receptor-ligand complex, also were observed. These

results provide visual evidence that MSH receptors are a property common to melanoma cells. Normal human epidermal melanocytes and keratinocytes were also shown to express melanotropin receptors by the same criteria established for melanoma cells.

L7 ANSWER 38 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1996:460540 BIOSIS
DOCUMENT NUMBER: PREV199699182896
TITLE: Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones.
AUTHOR(S): Li, Si-Jia; Varga, Karoly; Archer, Phillip; Hruby, Victor J.; Sharma, Shubh D.; Kesterson, Robert A.; Cone, Roger D.; Kunos, George [Reprint author]
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Virginia Commonwwealth Univ., Box 980613, Richmond, VA 23298, USA
SOURCE: Journal of Neuroscience, (1996) Vol. 16, No. 16, pp. 5182-5188.
CODEN: JNRSDS. ISSN: 0270-6474.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 11 Oct 1996
Last Updated on STN: 11 Oct 1996

AB Melanocortin peptides and at least two subtypes of melanocortin receptors (MC3-R and MC4-R) are present in brain regions involved in cardiovascular regulation. In urethane-anesthetized rats, unilateral microinjection of alpha-melanocyte-stimulating hormone (MSH) into the medullary dorsal-vagal complex (DVC) causes dose-dependent (125-250 pmol) hypotension and bradycardia, whereas y-MSH is less effective. The effects of alpha-MSH are inhibited by microinjection to the same site of the novel MC4-R/MC3-R antagonist SHU9119 (2-100 pmol) but not naloxone (270 pmol), whereas the similar effects of intra-DVC injection of beta-endorphin (1 pmol) are inhibited by naloxone and not by SHU9119. Hypotensive and bradycardic responses to electrical stimulation of the arcuate nucleus also are inhibited by ipsilateral intra-DVC microinjection of SHU9119. gamma-MSH and ACTH(4-10), but not alpha-MSH, elicit dose-dependent (0.1-12.5 nmol) pressor and tachycardic effects, which are much more pronounced after intracarotid than after intravenous administration. The effects of gamma-MSH (1.25 nmol) are not inhibited by the intracarotid injection of SHU9119 (1.25-12.5 nmol) or the novel MC3-R antagonist SHU9005 (1.25-12.5 nmol). We conclude that the hypotension and bradycardia elicited by the release of alpha-MSH from arcuate neurons is mediated by neural melanocortin receptors (MC4-R/MC3-R) located in the DVC, whereas the similar effects of beta-endorphin, a peptide derived from the same precursor, are mediated by opiate receptors at the same site. In contrast, neither MC3-R nor MC4-R is involved in the centrally mediated pressor and tachycardic actions of gamma-MSH, which, likely, are mediated by an as yet unidentified receptor.

L7 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:137750 CAPLUS
DOCUMENT NUMBER: 126:155849
TITLE: Melanotropic peptide receptors: membrane markers of human melanoma cells
AUTHOR(S): Jiang, Jinwen; Sharma, Shubh D.; Fink, Jody L.; Hadley, Mac E.; Hruby, Victor J.
CORPORATE SOURCE: Departments of Cell Biology & Anatomy, University of Arizona, Tucson, AZ, 85724, USA
SOURCE: Experimental Dermatology (1996), 5(6), 325-333
CODEN: EXDEEY; ISSN: 0906-6705
PUBLISHER: Munksgaard

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The objectives of this research were to determine whether melanotropin receptors are characteristic (constant) membrane markers of human melanoma cells. Methodologies were developed to visualize these receptors by fluorescence microscopy. Multiple copies (10-20) of both [Nle4,D-Phe7]α-MSH, a superpotent analog of α-MSH (α-MSH), and a fluorophore, were conjugated to polyvinyl alc. (PVA). Incubation in the presence of the multivalent macromol. conjugate (FITC-PVA-MSH) resulted in binding of human epidermal melanocytes and keratinocytes and human melanoma cells (both melanotic and amelanotic) to the fluorescent conjugate. Binding of the conjugate to the cells exhibited a unique cluster pattern (capping) suggesting a receptor internalization related phenomenon. Most importantly, every cell of every melanoma cell line, melanotic or amelanotic, possessed receptors as visualized by fluorescence microscopy. Since the cells were not synchronized, some binding apparently took place during all phases of the cell cycle. Therefore, receptor expression appears not to be cell-cycle dependent. Specificity of binding of FITC-PVA-MSH was demonstrated by several studies. Binding of the conjugate to melanoma cells could be blocked by prior incubation of the cells in the presence of the unconjugated hormone analog; [Nle4,D-Phe7]α-MSH. The macromol. conjugate lacking bound ligand (FITC-PVA) did not bind to the melanoma cells. Another peptide, a substance-P analog, attached to the substrate (FITC-PVA-SP) failed to bind to the cells. With the exception of keratinocytes, other cells of nonmelanocyte origin (e.g., fibroblasts, spleen, liver, kidney cells, and mammary cancer cells, lung cancer cells) did not bind to the conjugate. Thus, cell-specific melanotropin receptors appear to be characteristic cell surface markers of epidermal melanocytes, keratinocytes, and melanoma cells. In several human melanoma cell lines these receptors appeared to be functional since [Nle4,D-Phe7]α-MSH stimulated tyrosinase activity. Fluorescent melanotropin conjugates might prove useful in determining whether all human melanoma (primary and metastatic) tumors possess such receptors. These receptors might then provide targets for melanotropic peptides for the identification localization, and chemotherapy of melanoma.

L7 ANSWER 40 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 6

ACCESSION NUMBER: 1997:107433 BIOSIS
DOCUMENT NUMBER: PREV199799406636
TITLE: Human epidermal melanocyte and keratinocyte melanocortin receptors: Visualization by melanotropic peptide conjugated microspheres (Latex beads).
AUTHOR(S): Jiang, Jinwen; Sharma, Shubh D.; Hruby, Victor J.; Bentley, David L.; Fink, Jody L.; Hadley, Mac E. [Reprint author]
CORPORATE SOURCE: Dep. Cell Biol. Anatomy, Univ. Arizona, Tucson, AZ 85724-5044, USA
SOURCE: Pigment Cell Research, (1996) Vol. 9, No. 5, pp. 240-247. CODEN: PCREEA. ISSN: 0893-5785.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Mar 1997
Last Updated on STN: 10 Mar 1997

AB The objectives of this research were to determine whether melanocortin receptors are characteristic (constant) membrane markers of human epidermal melanocytes. Methodologies were developed to visualize melanotropin receptors by scanning electron microscopy (SEM). Multiple copies (up to a hundred) of

(Nle-4,D-Phe-7)alpha-MSH, a superpotent analog of alpha-melanocyte stimulating hormone (alpha-MSH), were conjugated to a macromolecular carrier (latex beads: microspheres). Incubation in the presence of the melanotropin-conjugated microspheres resulted in binding of human normal epidermal melanocytes to the beads. Almost every (possibly all) melanocyte possesses melanocortin receptors as visualized by SEM. Specificity of binding of the macromolecular conjugate was demonstrated by several studies: 1) Binding of melanocytes to the microspheres was specific since it could be blocked by prior incubation of the cells in the presence of the unconjugated hormone analog; 2) microspheres lacking bound ligand did not bind to the melanocytes; 3) microspheres that were first treated with reducing agents (e.g., dithiothreitol) did not subsequently bind to melanocytes; 4) another peptide hormone ligand (e.g., a substance-P analog) attached to the latex beads failed to bind to the cells; 5) B16/F10 mouse melanoma cells known to express melanocortin receptors bound to the microspheres; and 6) cells of nonmelanocyte origin (e.g., mammary cancer cells, small-cell lung cancer cells, fibroblasts) did not bind to the macromolecular conjugate. One exception was that human epidermal keratinocytes also expressed melanocortin receptors as determined by all the criteria established above for epidermal melanocytes. Thus, cell specific melanocortin receptors appear to be characteristic cell surface markers of epidermal melanocytes and keratinocytes.

L7 ANSWER 41 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 7

ACCESSION NUMBER: 1997:105459 BIOSIS
DOCUMENT NUMBER: PREV199799404662
TITLE: Melanocortin receptors: Identification and characterization by melanotropic peptide agonists and antagonists.
AUTHOR(S): Hadley, Mac E. [Reprint author]; Hruby, Victor J.; Jiang, Jiwen; Sharma, Shubh D.; Fink, Jody L.; Haskell-Luevano, Carrie; Bentley, David L.; Al-Obeidi, Fahad; Sawyer, Tomi K.
CORPORATE SOURCE: Cell Biol. Anatomy, Coll. Med., Tucson, AZ 85724-5044, USA
SOURCE: Pigment Cell Research, (1996) Vol. 9, No. 5, pp. 213-234. CODEN: PCREEA. ISSN: 0893-5785.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Mar 1997
Last Updated on STN: 10 Mar 1997

AB Hormones are chemical messengers released from cells to act on and control the activity of other cells. Hormonal ligands initiate their actions by interacting with receptive substances (Langley, 1906) of the target cells. These receptors are proteins that are either integral components of the cell membrane or are localized cytoplasmically within cells. Ligand-receptor interaction results in either the stimulation or inhibition of cellular activity. Since most hormones bind rather specifically to receptors possessed by their target cells, labeling of hormonal ligands can be utilized to identify and localize cells within an animal. In this report we discuss what is presently known about melanocortin receptors (MCRs) as studied by the use of labeled melanotropic peptide ligands.

L7 ANSWER 42 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 8

ACCESSION NUMBER: 1995:489989 BIOSIS
DOCUMENT NUMBER: PREV199598504289
TITLE: Cyclic Lactam alpha-Melanotropin Analogues of Ac-Nle-4-cyclo(Asp-5,D-Phe-7,Lys-10) alpha-

Melanocyte-Stimulating Hormone-(4-10)-NH-2 with Bulky Aromatic Amino Acids at Position 7 Show High Antagonist Potency and Selectivity at Specific Melanocortin Receptors.

AUTHOR(S): Hruby, Victor J. [Reprint author]; Lu, Dongsi; Sharma, Shubh D.; Castrucci, Ana De L.; Kesterson, Robert A.; Al-Obeidi, Fahad A.; Hadley, Mac E.; Cone, Roger D.
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ 85721, USA
SOURCE: Journal of Medicinal Chemistry, (1995) Vol. 38, No. 18, pp. 3454-3461.
CODEN: JMCMAR. ISSN: 0022-2623.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Nov 1995
Last Updated on STN: 14 Dec 1995

AB The cloning of the melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) receptors (MC1-R and MC2-R, respectively) recently has led to the identification of three additional melanocortin receptors, MC3-R, MC4-R, and MC5-R. The MC2 receptor primarily recognizes only ACTH peptides, but the other four receptors all recognize alpha-melanocyte-stimulating hormone (alpha-MSH) and potent alpha-MSH agonists such as (Nle-4,D-Phe-7)alpha-MSH-NH-2 and Ac-Nle-4-c(Asp-5,D-Phe-7 Lys-10)alpha-MSH-(4-10)-NH-2 as well as ACTH. The absence of any known physiological role for these new receptors, expressed both in the brain (MC3-R and MC4-R) and throughout a number of peripheral tissues (MC5-R), has necessitated a search for potent and receptor selective-agonists and antagonists. We report here that analogues of the superpotent cyclic agonist analogue Ac-Nle-4-c(Asp-5,D-Phe-7,Lys-10)alpha-MSH-(4-10)-NH-2, in which a bulky aromatic amino acid is substituted in the 7-position, can produce potent and selective antagonists for melanocortin receptors. Thus, the D-p-iodophenylalanine-7-containing analogue Ac-Nle-4-c(Asp-5,D-Phe(pI)-7,Lys-10)alpha-MSH-(4-10)-NH-2 is a potent antagonist (pA-2 = 10.3) in the classical frog skin (Rana pipiens) assay (MC1-R), as is the D-2'-naphthylalanine-7 (D-Nal(2)-7)-containing analogue Ac-Nle-4-c(Asp-5,D-Nal(2)-7, Lys-10)alpha-MSH-(4-10)-NH-2 (pA-2 gt 10.3). Interestingly, the D-p-chloro- and D-p-fluorophenylalanine-7-containing analogues lacked antagonist activities at all melanotropin receptors, and both exhibited full agonist potency in the frog skin assay. The activity of these analogues also was examined at four mammalian melanocortin receptors. Interestingly, Ac-Nle-4-c(Asp-5,(D-Nal(2)-7, Lys-10)alpha-MSH-(4-10)-NH-2 was found to be a potent antagonist of the MC4-R (pA-2 = 9.3) with minimal agonist activity, a less potent antagonist of the MC3-R (pA-2 = 8.3) with minimal agonist activity, and a full agonist of the MC1 and MC5 receptors. Surprisingly, Nle-4-c(Asp-5,D-Phe(pI)-7,Lys-10)alpha-MSH was found to be a potent agonist at the cloned human MC1-R (EC-50 = 0.055 nM) and mouse MC1-R (EC-50 = 0.19 nM) but had potent antagonist activities at the human MC4-R (pA-2 = 9.7) and human MC3-R (pA-2 = 8.3) with significant partial agonist activities (EC-50 = 0.57 and 0.68 nM, respectively) as well. Thus, highly potent and receptor selective antagonist analogues can arise from substitution of the D-Phe-7 residue with a bulky aromatic amino acid. These analogues can be used to help determine the functional roles of these receptors.

L7 ANSWER 43 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 9

ACCESSION NUMBER: 1995:319499 BIOSIS
DOCUMENT NUMBER: PREV199598333799
TITLE: Design, synthesis, biology, and conformations of bicyclic alpha-melanotropin analogues.
AUTHOR(S): Haskell-Luevano, Carrie; Shenderovich, Mark D.; Sharma, Shubh D.; Nikiforovich, Gregory V.; Hadley, Mac E.; Hruby, Victor J. [Reprint author]

CORPORATE SOURCE: Dep. Chem., Univ. Ariz., Tucson, AZ 85721, USA
SOURCE: Journal of Medicinal Chemistry, (1995) Vol. 38, No. 10, pp. 1736-1750.
CODEN: JMCMAR. ISSN: 0022-2623.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 30 Jul 1995
Last Updated on STN: 30 Jul 1995

AB Seven side chain-constrained.bicyclic alpha-melanotropin (alpha-MSH) analogues were designed and synthesized, their conformations analyzed, and their biological properties examined in the frog skin and lizard skin bioassays. The structure of these analogues is based on the central sequence Ac-Cys-4-Xaa-5-His-6-DPhe-7-Arg-8-Trp-9-Cys-10-Lys-11-NH-2 (Xaa-5 = Asp or Glu) and has been extended on the N-terminal with the amino acids Ser-1-Tyr-2-Ser-3 and on the C-terminal with Pro-12-Val-13 to more closely resemble the native hormone alpha-MSH. The analogue Ac-Cys-4-Asp-5-His-6-DPhe-7-Arg-8-Trp-9-Lys-10-Cys-11-NH-2 also was synthesized, and its conformational and biological properties were examined. Design of these analogues was based upon the previously identified superpotent monocyclic peptides (Cys-4,DPhe-7,Cys-10)alpha-MSH(4-10)-NH-2 and (Nle-4,Asp-5,DPhe-7,Lys-10)alpha-MSH(4-10)-NH-2 with the rationale of increasing conformational constraints to restrict the available backbone conformations as a means to identify the conformations that facilitate biological activity. Computer-assisted conformational analysis of the central tetrapeptide residues 6-9 identified beta-turns which varied with respect to the residue in the i + 1 position. Each highly constrained peptide contains D-Phe-7 and a 23-membered ring which has previously been identified as crucial to produce prolonged acting peptides with superagonistic activities. The bicyclic peptides reported in this study are full agonists and are 25-400-fold less potent than alpha-MSH in the frog and lizard skin bioassays.

L7 ANSWER 44 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 10
ACCESSION NUMBER: 1996:110536 BIOSIS
DOCUMENT NUMBER: PREV199698682671
TITLE: The melanotropic peptide, (Nle-4, D-Phe-7)alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation.
AUTHOR(S): Jiang, Jinwen; Sharma, Shubh D.; Nakamura, Shelley; Lai, Jeng-Yu; Fink, Jody L.; Hruby, Victor J.; Hadley, Mac E. [Reprint author]
CORPORATE SOURCE: Cell Biol. Anatomy, Coll. Med., Univ. Arizona, Tucson, AZ 85724, USA
SOURCE: Pigment Cell Research, (1995) Vol. 8, No. 6, pp. 314-323.
CODEN: PCREEA. ISSN: 0893-5785.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Mar 1996
Last Updated on STN: 13 Mar 1996

AB Seventeen human melanoma cell (HMC) lines, both melanotic and amelanotic, were incubated in the continuous presence of a potent melanotropic peptide hormone analog, (Nle-4,D-Phe7)alpha-MSH, for 72 hr with daily changes of medium. Only one cell line (HD, melanotic) consistently responded to the hormone analog by increased tyrosinase activity. Three (one melanotic, two amelanotic) of the HMC lines also failed to respond to the peptide by either increased or decreased enzyme activity when incubated continuously in the presence of the peptide for longer periods of time (6,15,27,43 days). The HD cell line, however, again responded with increasingly enhanced basal enzyme activity the longer the cells were incubated in the presence of the melanotropin. One amelanotic cell line (C8161) responded with enhanced enzyme activity when grown to confluency in the

continuous presence of the peptide. Basal tyrosinase activity of the C8161 cell line may have increased as cell density in the flasks increased. These results suggest that under conditions of increased cell number, phenotypic expression of tyrosinase activity in so called "amelanotic" (tyrosinase-negative) cells is increased and can be enhanced further by stimulation with a melanotropic peptide. Under conditions of increased cell number, the presence of (Nle-4,D-Phe-7)alpha-MSH caused morphological differentiation (shape change); the cells became enlarged and very dendritic. The number of cells in monolayer (surface of the flask) and in the medium were drastically reduced in both melanotic and "amelanotic" cell lines incubated with (Nle-4,D-Phe-7)alpha-MSH. The data support other published reports that melanotropic peptides inhibit human melanoma cell growth (proliferation) in vitro, most likely through a cytostatic mechanism. (Nle-4,D-Phe-7)alpha-MSH also exhibited a prolonged (residual) inhibitory action on HD cell proliferation. In other words, inhibition of cell growth (proliferation) of the HMCs was evident even several days after removal of the melanotropic peptide from the incubation medium.

L7 ANSWER 45 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 11

ACCESSION NUMBER: 1994:452483 BIOSIS
DOCUMENT NUMBER: PREV199497465483
TITLE: Preformulation studies with melanotan-II: A potential skin cancer chemopreventive peptide.
AUTHOR(S): Lan, En-Ling; Ugwu, Sydney O.; Blanchard, James [Reprint author]; Fang, Xiaojun; Hruby, Victor J.; Sharma, Shubh
CORPORATE SOURCE: Dep. Pharmaceutical Sci., Coll. Pharmacy, Univ. Ariz., Tucson, AZ 85121, USA
SOURCE: Journal of Pharmaceutical Sciences, (1994) Vol. 83, No. 8, pp. 1081-1084.
CODEN: JPMSAE. ISSN: 0022-3549.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Oct 1994
Last Updated on STN: 16 Dec 1994

AB Melanotan-II (1) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) which tans the skin and is currently being evaluated for the prevention of sunlight-induced skin cancers. The dissociation constants of 1 were determined using potentiometric titration and ultraviolet spectrophotometry. The pK-a1 (histidine) and pK-a2 (arginine) were estimated to be 6.54 and 11.72, respectively. The apparent partition coefficient (PC) was measured at three pH values using both n-octanol and isooctane as the nonpolar phase. The PC(octanol) and DELTA-log PC at pH 7.35 were 2.82 and 1.05, respectively. These data, together with the observance of a bioavailability of 4.6% in the rat, indicate that 1 may be a suitable candidate for oral delivery. The data presented here are useful in developing an appropriate dosage form for 1.

L7 ANSWER 46 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 12

ACCESSION NUMBER: 1995:33242 BIOSIS
DOCUMENT NUMBER: PREV199598047542
TITLE: Multivalent melanotropic Peptide and Fluorescent Macromolecular Conjugates: New Reagents for Characterization of Melanotropin Receptors.
AUTHOR(S): Sharma, Shubh D.; Granberry, Michael E.; Jiang, Jinwen; Leong, Stanley P. L.; Hadley, Mac E.; Hruby, Victor J. [Reprint author]
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ 85721, USA
SOURCE: Bioconjugate Chemistry, (1994) Vol. 5, No. 6, pp. 591-601.

CODEN: BCCHES. ISSN: 1043-1802.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Jan 1995
Last Updated on STN: 26 Jan 1995

AB Radioreceptor binding studies have documented the presence of melanotropin receptors on some but not all of the various human melanoma cell lines that have been studied. Using a newly developed class of multivalent fluorescent melanotropin -macromolecular conjugates, we have demonstrated for the first time the presence of specific melanotropin receptors on all of the melanoma cell lines, both mouse and human, melanotic as well as amelanotic, that were investigated. The conjugates developed by us consisted of multiple copies of both a potent melanotropin analogue and a fluorophore, both arranged in a pendent fashion on a biologically inert macromolecule. While the multivalency of these conjugates may have established stronger binding with the melanotropin receptors on the cell surface (perhaps by establishing simultaneous multiple interactions), the presence of multiple copies of the fluorophore also greatly increased the level of detection in fluorescence labeling experiments. Membrane receptor-hormone-associated phenomena, such as capping and internalization of the receptor-ligand complex, also were observed. The details of these methods are described using B-16 mouse melanoma cells as a model system. The demonstration of MSH receptors as a common marker for melanoma suggests that this methodology might be employed for early clinical detection and anatomical localization of melanoma- These results also offer the possibility that substitution of the fluorophore in these conjugates by a chemical agent of (chemo-)therapeutic relevance may provide a powerful tool for site specific (tumor) targeting and cytotoxicity.

L7 ANSWER 47 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 13
ACCESSION NUMBER: 1994:132615 BIOSIS
DOCUMENT NUMBER: PREV199497145615
TITLE: Kinetics of degradation of a cyclic lactam analog of alpha-melanotropin (MT-II) in aqueous solution.
AUTHOR(S): Ugwu, Sydney O.; Lan, En-Ling; Sharma, Shubh; Hruby, Victor; Blanchard, James [Reprint author]
CORPORATE SOURCE: Dep. Pharmaceutical Sci., Coll. Pharm., Univ. Arizona, Tucson, AZ 85721, USA
SOURCE: International Journal of Pharmaceutics (Amsterdam), (1994) Vol. 102, No. 1-3, pp. 193-199.
CODEN: IJPHDE. ISSN: 0378-5173.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Mar 1994
Last Updated on STN: 24 Mar 1994

AB The kinetics of degradation of MT-II in aqueous buffered solution was studied in order to facilitate the formulation of a stable oral dosage form. A stability-indicating high-performance liquid chromatographic (HPLC) assay was used to measure the concentrations of MT-II remaining at various time periods. The rate of degradation of MT-II was studied as a function of pH, phosphate buffer concentration, temperature and ionic strength. Results indicated that the degradation of MT-II followed apparent first-order kinetics. The pH-rate profile showed that MT-II was most stable at approximately pH 5.0. Data obtained from this study also indicated that the degradation rate of this peptide was directly proportional to phosphate buffer concentration and temperature. The shelf-life of MT-II in aqueous buffer solutions at 25 degree C was 27 h. The activation energy was 7.5 kcal/mol. The degradation rate of MT-II appeared to be independent of the ionic strength of the aqueous buffered

solution.

L7 ANSWER 48 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 14

ACCESSION NUMBER: 1993:426424 BIOSIS
DOCUMENT NUMBER: PREV199345074049
TITLE: Melanotropic peptides for therapeutic and cosmetic tanning of the skin.
AUTHOR(S): Hadley, Mac E. [Reprint author]; Sharma, Shubh D. ; Hruby, Victor J.; Levine, Norman; Dorr, Robert T.
CORPORATE SOURCE: Dep. Anat., Univ. Ariz., Tucson, AZ 85724, USA
SOURCE: Vaudry, H. [Editor]; Eberle, A. N. [Editor]. Ann. N. Y. Acad. Sci., (1993) pp. 424-439. Annals of the New York Academy of Sciences; The melanotropic peptides. Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, New York 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Conference. Rouen, France. September 6-9, 1992.
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 0-89766-782-4 (paper), 0-89766-781-6 (cloth).
DOCUMENT TYPE: Article
Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Sep 1993
Last Updated on STN: 15 Sep 1993

L7 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:401389 CAPLUS
DOCUMENT NUMBER: 121:1389
TITLE: Melanotropic peptides and melanoma cell receptors
AUTHOR(S): Jiang, Jin-wen; Nakamura, Shelley; Sharma, Shubh D.; Hruby, Victor J.; Hadley, Mac E.
CORPORATE SOURCE: Coll. Med., Univ. Ariz., Tucson, AZ, 85724, USA
SOURCE: Pept.: Biol. Chem., Proc. Chin. Pept. Symp. (1993), Meeting Date 1992, 143-4. Editor(s): Du, Yu-cang; Tam, James P.; Zhang, You-shang. ESCOM: Leiden, Neth.
CODEN: 59YOAI
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A MSH analog attached to polyvinyl alc. through a disulfide linkage was used to demonstrate the presence of melanotropin receptors in various melanoma cell lines. The MSH conjugate bound to all mouse and human melanoma cells, but not to MCF-7 or to normal mouse spleen and liver cells.

L7 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:622219 CAPLUS
DOCUMENT NUMBER: 121:222219
TITLE: A new class of positively charged melanotropin analogs: a new concept in peptide design
AUTHOR(S): Sharma, Shubh D.; Nikiforovich, Gregory V.; Jiang, Jinwen; Castrucci, Ana M. L.; Hadley, Mac E.; Hruby, Victor J.
CORPORATE SOURCE: Department of Chemistry, University of Arizona, Tucson, AZ, 85721, USA
SOURCE: Pept. 1992, Proc. Eur. Pept. Symp., 22nd (1993), Meeting Date 1992, 95-6. Editor(s): Schneider, Conrad H.; Eberle, Alex N. ESCOM: Leiden, Neth.
CODEN: 60LUAN
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Comparative potencies relative to α- melanotropin in the frog and lizard skin assays were measured for 4 α-MSH1-13-NH2 analogs with increased overall pos. charges on the mols. Introduction of basic residues in a biocompatible fashion can further modulate and enhance the biol. profile.

L7 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:473927 CAPLUS
DOCUMENT NUMBER: 121:73927
TITLE: Melanotropic peptides for the identification, localization (imaging) and chemotherapy of melanoma
AUTHOR(S): Hadley, Mac E.; Sharma, Shubh D.; Hruby, Victor J.
CORPORATE SOURCE: Dep. Anat., Univ. Ariz., Tucson, AZ, 85721, USA
SOURCE: Pept.: Biol. Chem., Proc. Chin. Pept. Symp. (1993), Meeting Date 1992, 53-6. Editor(s): Du, Yu-cang; Tam, James P.; Zhang, You-shang. ESCOM: Leiden, Neth. CODEN: 59YOAI
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
AB A review, with 14 refs., on the design of α-MSH peptides for melanoma chemotherapy, fluorescent MSH analogs for receptor identification and visualization, radiolabeled MSH analogs, MSH peptides for protection against skin cancer, and MSH delivery.

L7 ANSWER 52 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 15
ACCESSION NUMBER: 1993:426398 BIOSIS
DOCUMENT NUMBER: PREV199345074023
TITLE: Design, synthesis, and conformation of superpotent and prolonged acting melanotropins.
AUTHOR(S): Hruby, Victor J. [Reprint author]; Sharma, Shubh D. ; Toth, Katalan; Jaw, John Y.; Al-Obeidi, Fahad; Sawyer, Tomi K.; Hadley, Mac E.
CORPORATE SOURCE: Dep. Chem., Univ. Ariz., Tucson, AZ 85721, USA
SOURCE: Vaudry, H. [Editor]; Eberle, A. N. [Editor]. Ann. N. Y. Acad. Sci., (1993) pp. 51-63. Annals of the New York Academy of Sciences; The melanotropic peptides. Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, New York 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Conference. Rouen, France. September 6-9, 1992.
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 0-89766-782-4 (paper), 0-89766-781-6 (cloth).
DOCUMENT TYPE: Article
Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Sep 1993
Last Updated on STN: 15 Sep 1993

L7 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:551354 CAPLUS
DOCUMENT NUMBER: 117:151354
TITLE: Multivalent ligands for diagnosis and therapeutics
AUTHOR(S): Sharma, Shubh D.; Hruby, Victor J.; Hadley, Mac E.; Granberry, Michael E.; Leong, Stanley P. L.
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA
SOURCE: Pept.: Chem. Biol., Proc. Am. Pept. Symp., 12th (1992), Meeting Date 1991, 599-600. Editor(s): Smith, John A.; Rivier, Jean E. ESCOM: Leiden, Neth.
CODEN: 57XGA9

DOCUMENT TYPE: Conference
LANGUAGE: English
AB A report from a symposium on the preparation of fluorescent melanotropin-polymer conjugates and their binding with a variety of cultured melanoma cells.

L7 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:524732 CAPLUS
DOCUMENT NUMBER: 117:124732
TITLE: Design of different conformational isomers of the same peptide: α- melanotropin
AUTHOR(S): Nikiforovich, Gregory V.; Sharma, Shubh D.; Hadley, Mac E.; Hruby, Victor J.
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA
SOURCE: Pept.: Chem. Biol., Proc. Am. Pept. Symp., 12th (1992), Meeting Date 1991, 389-92. Editor(s): Smith, John A.; Rivier, Jean E. ESCOM: Leiden, Neth.
CODEN: 57XGA9
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Cyclic analogs of an α-MSH fragment were examined for their biol. potencies and conformations. All analogs displayed full biol. responses, indicating that they were all capable of assuming the conformation involved in the transduction step. Differences in potencies reflected differences in ability to assume the conformation associated with receptor recognition and binding steps.

L7 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:185974 CAPLUS
DOCUMENT NUMBER: 114:185974
TITLE: Antisense peptides of melanocyte-stimulating hormone (MSH): surprising results
AUTHOR(S): Al-Obeidi, Fahad A.; Hruby, Victor J.; Sharma, Shubh D.; Hadley, Mac E.; Castrucci, Ana M. De L.
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA
SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 11th (1990), Meeting Date 1989, 530-2. Editor(s): Rivier, Jean E.; Marshall, Garland R. ESCOM Sci. Pub.: Leiden, Neth.
CODEN: 56XTA7
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A symposium report on the design and solid-phase synthesis of 8 antisense peptides related to β-MSH and 2 related to α-MSH. Antisense peptides are encoded by mRNA complementary to the mRNA for a specific peptide hormone. Melanotropic activities are given for the above antisense peptides.

=> d his

(FILE 'HOME' ENTERED AT 18:14:58 ON 22 DEC 2006)

FILE 'REGISTRY' ENTERED AT 18:15:14 ON 22 DEC 2006
L1 STRUCTURE UPLOADED
L2 8 L1 SAM SSS
L3 124 L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:16:31 ON 22 DEC 2006
L4 14 L3

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT 18:19:57 ON 22 DEC 2006

```
                E SHUBH SHARMA/AU
                E SHUBH S?/AU
                E SHARMA SHUBH?/AU
L5          130 E1-E8
L6           70 MELAN? AND L5
L7           55 DUP REM L6 (15 DUPLICATES REMOVED)

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   182.03     456.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -27.00     -38.25

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:26:57 ON 22 DEC 2006
```